The effects of garlic upon endothelial function, vascular inflammation, oxidative stress and insulin resistance in patients with type 2 diabetes at high cardiovascular risk : a double blind randomised placebo controlled trial by Atkin, Marc
 The effects of garlic upon endothelial function, 
vascular inflammation, oxidative stress and 
insulin resistance in patients with type 2 
diabetes at high cardiovascular risk. A double 
blind randomised placebo controlled trial. 
 
Dr Marc Atkin 
BM MRCP 
 
In collaboration with: 
Academic Unit of Diabetes and Endocrinology, 
Queen Alexandra Hospital, Portsmouth 
 
This thesis is submitted in partial fulfilment of the 
requirements for the award of the degree of Doctor of 
Medicine of the University of Portsmouth 
Submitted May 2011 
  
2 
 
 
 
 
DECLARATION 
 
Whilst registered as a candidate for the above degree, I 
have not been registered for any other research award. 
The results and conclusions embodied in this thesis are 
the work of the named candidate and have not been 
submitted for any other academic award. 
 
Signature: 
  
3 
 
Table of Contents 
Acknowledgements .................................................................................................................................... 9 
List of Figures ............................................................................................................................... 10 
List of Tables................................................................................................................................. 11 
List of Abbreviations used .......................................................................................................................... 13 
Dissemination ................................................................................................................................ 16 
Abstract ......................................................................................................................................... 17 
CHAPTER 1: INTRODUCTION .............................................................................................. 19 
1.1 Diabetes Mellitus 
1.1.1 Definition .............................................................................................................................. 19 
1.1.2 Epidemiology ........................................................................................................................ 21 
1.1.3 Mortality and morbidity in type 2 diabetes ........................................................................... 21 
1.1.4 Pathophysiology .................................................................................................................... 22 
1.2 Traditional risk factors for cardiovascular disease ......................................................................... 32 
1.3 Novel risk factors ................................................................................................................................ 33 
1.3.1 Role of oxidative stress in diabetes ....................................................................................... 36 
1.3.2 Potential sources of Reactive Oxygen Species in diabetes ................................................... 38 
1.3.3 Reduced antioxidant defence in diabetes .............................................................................. 40 
1.3.4 Oxidative stress and complications of diabetes .................................................................... 41 
  
4 
 
1.3.5 Role of vascular inflammation in diabetes ............................................................................ 42 
1.3.6 Vascular inflammation and complications of diabetes ......................................................... 43 
1.3.7 Role of endothelial dysfunction in diabetes .......................................................................... 44 
1.3.8 Endothelial dysfunction as a source of insulin resistance ..................................................... 45 
1.3.9 Endothelial dysfunction and complications of diabetes ........................................................ 46 
1.4 The Common soil hypothesis of diabetes; the relationship between oxidative stress, vascular 
inflammation, endothelial dysfunction, insulin resistance and diabetes .............................................. 47 
1.5 Garlic .................................................................................................................................................... 49 
1.5.1 Medicinal history of garlic .................................................................................................... 49 
1.5.2 Active ingredients and metabolism of garlic ........................................................................ 50 
1.5.3 Garlic as a therapeutic agent ................................................................................................. 55 
1.5.4 Garlic and oxidative stress .................................................................................................... 56 
1.5.5 Garlic and endothelial dysfunction ................................................................................ 58 
1.5.6 Garlic and inflammation .......................................................................................... 59 
1.5.7 Garlic and insulin resistance .................................................................................... 61 
1.5.8 Garlic and blood pressure......................................................................................... 62 
1.5.9 Garlic and LDL cholesterol ...................................................................................... 64 
1.6 Aims and Hypotheses ............................................................................................................ 66 
CHAPTER 2: METHODS ......................................................................................................... 67 
2.1 Subjects .................................................................................................................................. 67 
  
5 
 
2.2 Clinical Protocol .................................................................................................................... 68 
2.3 Metabolic markers ................................................................................................................ 70 
2.4 Homeostasis Model Assessment ........................................................................................... 70 
2.5 Oxidative stress markers ...................................................................................................... 73 
2.5.1 GSH/GSSG (Glutathione Ratio) .............................................................................. 73 
2.5.2 Plasma Lipid Hydroperoxides (LHP)....................................................................... 75 
2.5.3 Plasma Total Antioxidant Status (TAOS) ................................................................ 76 
2.6 Biochemical markers of inflammation ................................................................................ 78 
2.6.1 Highly sensitive C-reactive protein (hsCRP) ........................................................... 78 
2.7 Measurement of endothelial function .................................................................................. 78 
2.7.1 Digital Plethysmography .......................................................................................... 78 
2.7.2 Urinary Albumin Creatinine Ratio ........................................................................... 84 
2.8 Statistical Analysis ................................................................................................................ 84 
CHAPTER 3: RESULTS  ........................................................................................................... 86 
3.1 Subjects .................................................................................................................................. 86 
3.2 Baseline characteristics ......................................................................................................... 86 
3.2.1 Baseline metabolic markers ..................................................................................... 90 
3.3 Effect of AGE and placebo upon measured outcomes ....................................................... 92 
3.3.1 Weight change .......................................................................................................... 92 
  
6 
 
3.3.2 Systolic blood pressure ............................................................................................ 93 
3.3.3 Diastolic blood pressure ........................................................................................... 95 
3.3.4 Plasma total cholesterol............................................................................................ 96 
3.3.5 Plasma HDL cholesterol .......................................................................................... 98 
3.3.6 Plasma triglyceride ................................................................................................. 100 
3.3.7 Fructosamine .......................................................................................................... 102 
3.3.8 Insulin resistance .................................................................................................... 104 
3.4 Markers of endothelial function ........................................................................................ 106 
3.4.1 Digital Plethysmography ........................................................................................ 106 
3.4.2 Urinary albumin creatinine ratio ............................................................................ 109 
3.5 Markers of oxidative stress ................................................................................................ 111 
3.5.1 Plasma Total Antioxidant Status (TAOS) .............................................................. 111 
3.5.2 Glutathione ratio..................................................................................................... 113 
3.5.3 Whole blood glutathione ........................................................................................ 115 
3.5.4 Plasma Lipid Hydroperoxides (LHP)..................................................................... 117 
3.6 Markers of vascular inflammation .................................................................................... 119 
3.6.1 Plasma hsCRP ........................................................................................................ 119 
3.7 Summary of results ............................................................................................................. 121 
3.8 Subset Analysis .................................................................................................................... 122 
  
7 
 
 
3.9 Associations .......................................................................................................................... 124 
3.10 Adverse events ................................................................................................................... 127 
CHAPTER 4: DISCUSSION  .................................................................................................. 128 
4.1 Previous clinical studies examining the effect of garlic on metabolic parameters ........ 129 
4.1.1 AGE and oxidative stress ....................................................................................... 130 
4.1.2 AGE and endothelial function ................................................................................ 134 
4.1.3 AGE and vascular inflammation ............................................................................ 135 
4.1.4 AGE and insulin resistance .................................................................................... 137 
4.2 AGE and traditional risk factors for cardiovascular disease ......................................... 137 
4.2.1 Blood Pressure ....................................................................................................... 137 
4.2.2 Lipid Metabolism ................................................................................................... 138 
4.3 Associations .......................................................................................................................... 139 
4.4 Limitations of present study ............................................................................................... 142 
4.4.1 Cohort ..................................................................................................................... 142 
4.4.2 Methodology .......................................................................................................... 143 
4.4.3 Endothelial Function .............................................................................................. 144 
4.4.4 Oxidative stress markers ........................................................................................ 146 
4.4.5 Circulating markers of inflammation ..................................................................... 146 
  
8 
 
4.4.6 Measurement of insulin resistance ......................................................................... 148 
4.5 AGE as a therapeutic agent ................................................................................................ 149 
4.6 Conclusion and future direction ........................................................................................ 149 
REFERENCES  ......................................................................................................................... 151 
  
9 
 
ACKNOWLEDGEMENTS 
I would like to thank: 
Professor Michael Cummings – First Supervisor 
Dr David Laight - Supervisor 
Ms Sharon Allard- Research Nurse, QAH. - for help in dealing with subjects 
Dr Anthony Wierzbicki & Dr Joseph Cheung - for their laboratories help with processing the 
HsCRP samples 
Professor Ian Cree – for use of the cancer laboratory, QAH 
Dr Partha Kar – for his support and guidance 
Dr Georgina Page – for help in consolidating results 
Dr Nagatoshi Ide, Wakunaga Pharmaceuticals Ltd – for guidance in use of AGE 
Wakunaga Pharmaceuticals Ltd – for supply of AGE capsules 
Ms Heather Cuell, Pharmacist – for dispensing AGE and randomisation 
Reuben Ogollah – for statistical advice 
The GP practices who allowed me to recruit subjects from their diabetes patients‘ database.  
The subjects who volunteered to take part in the study. 
My family- for putting up with the years of study 
  
10 
 
List of Figures 
Figure 1: Progression of metabolic decompensation over time with type 2 diabetes 
Figure 2: Insulin signalling pathways in the endothelial cells 
Figure 3: Common Soil diagram 
Figure 4: Pathways of reactive oxygen species production and clearance 
Figure 5: Polyol pathway of glucose metabolism 
Figure 6: Proposed metabolism of Allicin 
Figure 7: Processing of garlic gives different end products 
Figure 8: Clinical Protocol Schematic 
Figure 9: Screenshot of the HOMA IR calculator 
Figure 10: Diagrams of the typical digital pulse waveforms obtained 
Figure 11: Calculation of Reflective Index 
Figure 12: Percentage of subjects on vasoactive medications 
Figure 13: Percentage of active smokers amongst group 
Figure 14: Correlation between body mass index and insulin resistance 
Figure 15: Correlation between GSH/GSSG ratio and insulin resistance 
  
11 
 
List of Tables 
Table 1: WHO classification of diabetes mellitus 
Table 2: Reversible and non-reversible risk factors for vascular disease 
Table 3: Major constituents of widely used garlic preparations 
Table 4: Table 4: Summary of studies investigating garlic‘s effect on blood pressure in non-
diabetic subjects. 
Table 5: Summary of studies investigating garlic‘s effect on lipids in non-diabetic 
hyperlipidaemic subjects 
Table 6: Dawber‘s classification of Digital Volume Pulse 
Table 7: Baseline characteristics of subjects 
Table 8: Baseline metabolic parameters of subjects 
Table 9: Baseline comparisons before and after washout period 
Table 10: Weight change after 4 weeks treatment 
Table 11: Changes in Systolic blood pressure 
Table 12: Changes in Diastolic blood pressure 
Table 13: Changes in plasma total cholesterol 
Table 14: Changes in HDL cholesterol 
  
12 
 
Table 15: Changes in plasma triglycerides 
Table 16: Changes in Fructosamine 
Table 17: Changes in insulin resistance 
Table 18: Reflective Index change post Salbutamol 
Table 19: Reflective Index change post GTN 
Table 20: Changes in urinary albumin/creatinine ratio 
Table 21: Changes in TAOS 
Table 22: Changes in glutathione ratio 
Table 23: Changes in whole blood glutathione 
Table 24: Changes in LHP 
Table 25: Changes in plasma hsCRP 
Table 26: Summary of the effect of AGE and placebo on measured parameters 
Table 27: Comparisons of baselines in men and women 
Table 28: ANOVA analysis of men and women subsets 
Table 29: Table of Correlations 
Table 30: Characteristics of previous clinical studies using garlic to examine metabolic 
parameters 
  
13 
 
List of Abbreviations 
ABTS: 2,2‘-azino-bis(3-
ethylbenzthiazoline-6-sulfonic acid) 
ACEI: Angiotensin converting enzyme 
inhibitor 
ACR: Albumin Creatinine ratio 
ACSO: S-Allyl-L-cysteine Sulphoxides  
AEAC: Ascorbate Equivalent Antioxidant 
Concentration 
AGE: Aged Garlic Extract 
AGEPs: Advanced Glycation End Products 
AMP: Adenosine monophosphate 
AMS: Allyl methyl Sulphide 
AMSO: Allyl methyl Sulphone 
ANOVA: Analysis of variance 
BMI: Body mass index 
CO: Crossover study 
CHD: Coronary Heart disease 
CV: Coefficient of variance 
DAS: Diallyl suphides 
DATS: Diallyl trisulfide 
DTNB: 5,5‘-dithio-bis(2-nitrobenzoic acid) 
DVP: Digital Volume Pulse 
DVW: Digital Volume waveform 
ECG: Electrocardiogram 
EDTA: Ethylenediamine tetraacetic acid 
ELAM-1: Endothelial leucocyte adhesion 
molecule-1 
eNOS: Endothelial nitric oxide synthase 
FFA: Free fatty acids 
FMD: Flow mediated dilatation 
FRAP: Ferric reducing ability of plasma 
GIP: Gastrointestinal Peptide 
  
14 
 
GLP: Glucagon-like peptide 
GLUT-1: Glucose transporter protein type 
1 
GSH/GSSG: Glutathione ratio 
GSH: Glutathione 
GSSG: Oxidized glutathione  
GTN: Glyceryltrinitrate 
HbA1c: Glycosylated haemoglobin 
HDL: High density lipoprotein 
HMG-CoA: 3-Hydroxy-3-Methyl-Glutaryl 
Coenzyme A  
HOMA-B: Homeostasis Model 
Assessment- Beta cells 
HOMA-IR: Homeostasis Model 
Assessment- Insulin Resistance 
HPLC: High Performance Liquid 
Chromatography 
HsCRP: Highly sensitive C-reactive 
protein 
ICAM: Intercellular adhesion molecule 
IL-6: Interleukin 6 
iNOS: Inducible nitric oxide synthase 
INR: International Normalised Ratio 
JNK: c-Jun N-Terminal Kinase 
KS test: Kolmogorov-Smirnov test 
LDL: Low density lipoprotein 
LHP: Lipid hydroperoxides 
MAPK: Mitogen activated Protein Kinase
  
15 
 
MCP-1: Monocyte chemotactic protein-1 
MDA: malonaldehyde 
NADPH: Nicotinamide adenine 
dinucleotide 
NF-kappa B: Nuclear factor kappa beta 
NO: Nitric oxide 
NOS: Nitric Oxide Synthase 
PC: Placebo controlled study 
PWV: Pulse wave velocity 
RAGE: Receptor for Advanced glycation 
end products 
RI: Reflective index 
RIA: Radioimmunoassay 
ROS: Reactive Oxygen Species 
SAC: S-Allyl Cysteine 
SAMC: S- Allyl Methyl Cysteine 
SAPK: Stress-activated protein kinase  
SD: Standard Variation 
sICAM-1: soluble intercellular adhesion 
molecule type 1 
SSA:  Sulpho-salicylic acid 
TAC: Total Anti-oxidant capaciity 
TAOS: Total antioxidant status 
TBARS: ThioBarbituric Acid Reactive 
Substances 
TEA: Triethonalamine 
TNF-α: Tumour necrosis factor alpha 
UKPDS:  United Kingdom Prospective 
Diabetes Study 
VCAM-1: Vascular cell adhesion 
molecule-1 
WHO: World Health Organisation 
WHO: World Health Organisation
 16 
 
Dissemination 
 Diabetes UK Annual Professional Conference, Liverpool, March 2010  
 
 The effects of Garlic upon endothelial function and vascular 
inflammation in patients with type 2 diabetes at high cardiovascular risk 
 
 Is there an association between markers of inflammation and 
endothelial function in individuals with type 2 diabetes? 
 
 
Medical Research Society, Royal College of Physicians, Feb 2010 
  The effects of Garlic upon oxidative stress in patients with type 2 
diabetes at high cardiovascular risk 
 
University of Portsmouth Postgraduate Research Review, July 2009 
  The effects of Garlic upon endothelial function, vascular inflammation, 
oxidative stress and insulin resistance in patients with type 2 diabetes at 
high cardiovascular risk.  
 
Association British Clinical Diabetologists Meeting, Harrogate, Nov 2009 
 The effects of Garlic upon modifiable cardiovascular risk factors and 
insulin resistance in patients with type 2 diabetes at high cardiovascular 
risk 
 
 17 
 
Abstract 
Background and aims 
Endothelial dysfunction, vascular inflammation and oxidative stress have been integrally 
linked to the pathogenesis of both type 2 diabetes and cardiovascular disease. Aged Garlic 
Extract (AGE), a potent antioxidant, has been shown in previous studies to attenuate these 
novel risk factors in a non-diabetic population. 
Aims 
This study tested the hypothesis that AGE may improve endothelial function , oxidative stress, 
vascular inflammation and insulin resistance in high risk cardiovascular subjects with type 2 
diabetes (defined as >30% Cardiovascular risk over 10 yrs). 
Methods  
A double blind, placebo controlled cross-over study was performed in 26 type 2 diabetic 
patients who received 1200mg of AGE or placebo daily for 4 weeks with a 4 week washout 
period. Plasma HsCRP was measured as a marker of inflammation. TAOS,GSH/GSSG and 
LHP were measured as markers of  oxidative stress/anti-oxidant defence. Insulin resistance 
was measured using the HOMA-IR method. Endothelial function was measured using change 
in the reflective index (RI) post salbutamol using digital photoplethysmography and urinary 
albumin/creatinine ratio was measured as a biochemical surrogate. Measurements were taken 
at baseline and after intervention with AGE  or placebo. 
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Results 
Of the 26 patients studied (Male 17, Female 9), mean age was 61 ± 8 yrs, HbA1c 7.2 ±1.1%, 
BP 130/75 ±15.9/9.8 mmHg , total cholesterol  4.2 ±0.81mmol/l, triglyceride 2.11 ± 
1.51mmol/l, HDL-cholesterol 1.04  ± 0.29mmol/l. The majority of patients were being treated 
with metformin (59%), aspirin (50%) and statin (96%) therapy. 36% were treated with an 
ACEI. There were no changes in these therapies throughout the study. 
Treatment with AGE had no significant effect upon the above metabolic parameters including 
insulin resistance. Systolic blood pressure pre AGE 130± 15mmHg vs post AGE 130± 
14mmHg. Total cholesterol pre AGE 4.2±0.9mmol/l vs post AGE 4.2±0.8mmol/l. 
Triglycerides pre AGE 1.4 IQ range 0.7 mmol/l vs post AGE 1.4 IQ range 0.8 mmol/l. HDL 
cholesterol pre AGE 1.0 ± 0.3 mmol/l vs post AGE 1.0 ± 0.3mmol/l. In addition, no 
statistically significant difference was found in plasma HsCRP (pre AGE: median 2.0mg/l,  IQ 
range 0.8-2.7 vs post AGE: median 1.83mg/l, IQ range 1.1-3.2, p =0.89) or urinary 
albumin/creatinine ratio (pre AGE: 0.55, IQ range 0.4-1.65 vs post AGE: 0.6, IQ range 0.47-
1.5, p = 0.43) endothelial function (change in RI pre AGE:  6.5%, IQ range 2.75-11 vs post 
AGE:  6.5%,  IQ range 2.75-13, p = 0.95) with AGE or placebo. 
Conclusion 
In this group of type 2 diabetic patients at high cardiovascular risk, 4 weeks treatment with 
AGE did not significantly improve endothelial function, vascular inflammation, oxidative 
stress or insulin resistance. 
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Chapter 1: Introduction 
 
1.1 Diabetes Mellitus 
Diabetes Mellitus describes a collection of metabolic derangements characterised by chronic 
hyperglycaemia. The hyperglycaemic state may derive from defects in insulin secretion, end 
organ resistance or a combination of both. Persistent hyperglycaemia and insulin deficiency 
can cause acute complications with significant mortality or more commonly, chronic 
complications in both the macro and microvasculature which shorten life expectancy and full 
health. 
1.1.1 Definition  
The World Health Organisation (WHO) criteria for diagnosis of diabetes mellitus is a fasting 
glucose greater than or equal to 7.0mmol/l, a random plasma glucose of greater than or equal 
to 11.1mmol/l with symptoms or 2 abnormal blood tests, or a plasma glucose of greater than 
or equal to 11.1mmol/l 2 hours after a 75g oral glucose tolerance test. [1] 
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Table 1:  WHO classification of Diabetes 
 
The WHO (World Health Organisation) has classified diabetes into several types (table), the 
majority of which fall into type 1 and type 2 diabetes. Type 1 is characterized by an immune 
mediated destruction of pancreatic beta cells which results in an absolute deficiency of insulin 
secretion. Diagnosis can be aided by measuring circulating antibodies and a reduction in 
plasma C- peptide levels as a marker of beta cell dysfunction. 
The more common Type 2 diabetes represents over 90% of cases and develops as a 
consequence of end organ resistance to insulin and an inadequate compensatory insulin 
secretory response. 
 
Type of Diabetes Main pathological Defect Percentage of DM cases 
Type 1 
Autoimmune, Islet cell 
destruction (insulin 
deficiency) 
5-25% 
Type 2 Peripheral insulin resistance 75-95% 
Type 3 
Insulin deficiency ±resistance 
(genetic, endocrine causes etc) 
<1% 
Type 4 
Insulin resistance in 
pregnancy (gestational 
diabetes) 
Approx 3.5% pregnancies
2
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1.1.2 Epidemiology 
It is estimated that 2.4 million people had diabetes in England in 2008 [3], giving a prevalence 
of 4.67%. A recent study showed an average annual increase in prevalence of diabetes of 4.9% 
or a 10 year increase of 54%. Most of this rise is due to type 2 diabetes (97%). The cause of 
this increase has been attributed to increasing obesity and an ageing population [4]. Type 2 
diabetes is more common amongst certain ethnic groups and in under privileged areas [5]. 
The rapid rise in the prevalence of diabetes is not simply an English phenomenon. Worldwide 
some 246 million people were estimated to have diabetes in 2004, which is predicted to rise to 
333 million by 2025 [6]. 
1.1.3 Mortality & Morbidity in Diabetes  
Diabetes continues to inflict a huge cost on individuals and health care systems. 
In England people with diabetes aged between 20 and 79 years are approximately twice as 
likely to die as people without diabetes (Diabetes in England) and it is estimated that there 
were 26,300 excess deaths from diabetes in 2005.  This equates to an approximate reduction of 
life expectancy of 17 years in a 45 year old male with type 2 diabetes [7, 8]. 
Cardiovascular and cerebrovascular disease accounts for approximately 80% [3] of mortality 
in those with diabetes. Mortality rates from heart disease in adults with diabetes are between 
two to four times higher than in adults without the condition [9, 10] and those with diabetes 
have a risk of a stroke two to four times higher than those without diabetes. [11]. 
For those that live with diabetes, chronic complications are a burden. It is estimated within 20 
years of diagnosis, nearly all people with Type 1 diabetes and approximately 60% of 
individuals with Type 2 diabetes will have a degree of diabetic retinopathy [12]. Diabetes is 
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also the single largest cause of blindness among people of work age in the United Kingdom 
[13].  
About 30% of people with Type 2 diabetes develop overt renal disease [14]. In 2006/07 there 
were 5015 lower limb amputations in people with diabetes in England [15]. 
In 2006/7 the total NHS expenditure on the diabetes care programme was £1,043 million and 
this does not include expenditure in general practice [3]. 
1.1.4 Pathophysiology 
Type 1 diabetes 
Type 1 diabetes is caused by a destruction of pancreatic beta cells which is thought to be 
autoimmune in origin. This is supported histologically by the presence of an inflammatory 
infiltrate in the Islets of Langerhans in the pancreas and the presence of circulating islet cell 
antibodies in those with newly diagnosed type 1 diabetes, although these findings are not 
universal. 
The cause of type 1 diabetes remains uncertain. Population clusters suggest a genetic 
predisposition but there is speculation that this requires an environmental trigger. Several 
triggers have been implicated such as gut viruses [16] and Vitamin D deficiency [17]. 
Type 2 diabetes 
Type 2 diabetes is thought to originate from progressive beta cell failure on the background of 
insulin resistance, giving a relative insulin deficiency and subsequent hyperglycaemia. 
End organ resistance is characterized by increased hepatic glucose production and impaired 
glucose handling by skeletal muscle and adipose tissue. This gives a compensatory 
hyperinsulinaemia. Initially this is adequate to prevent hyperglycaemia, however, as beta cell 
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function declines the ability to maintain this insulin hypersecretion is lost and hyperglycaemia 
and type 2 diabetes ensue. (See figure 1)  
 
Figure 1: Progression of metabolic decompensation over time with type 2 diabetes. PPG = 
Post-prandial plasma glucose levels, FPG = Fasting Plasma glucose levels 
Normal Physiology of Glucose transport and insulin secretion 
Glucose Transporters 
There are a variety of facilitative glucose transporters (GLUTs) on the cellular membrane 
which vary in their affinity and their specificity for sugars and tissue distribution. Initially 5 
GLUTs were identified and are the best described, GLUT 1-4 being glucose transporters and 
GLUT-5 a fructose transporter. GLUTs 6 -14 have since been identified [411]. GLUT 
distribution in mammalian cells is widespread including liver skeletal muscle, vascular 
endothelial cells and the blood brain barrier. 
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 GLUT-1 is widely found in human tissues but is particularly abundant in blood brain barrier 
endothelial cells, fibroblasts and erythrocytes. GLUT-1 is thought to be responsible for the 
high volume transport of glucose across the blood brain barrier and is generally insensitive to 
insulin. However, GLUT-1 in adipose tissue has been shown to be insulin sensitive and to 
translocate to the plasma membrane in the presence of insulin in a manner similar to GLUT-4 
in skeletal muscle suggesting a regulatory role [409]. This effect has also been found to be 
enhanced by the insulin sensitiser metformin which may be a window on its mode of action 
[410].  
GLUT-2 is a low affinity high turnover glucose transporter found in liver cells, small intestine 
and kidney and may regulate glucose transport in response to nutritional status [408]. It is also 
the main glucose transporter in pancreatic beta cells. One of the characteristics of the GLUT 2 
transporter is that its glucose transport is dependent on the prevailing glucose concentration 
rather than the expression of the transporter thus it is not saturated by physiological 
concentrations of glucose [411]. 
Glucose metabolism and transport in endothelial cells 
Glucose is metabolised by endothelial cells mainly by glycolytic processes at normal 
physiological glucose concentrations. This gives the endothelial cell some degree of protection 
against low glucose levels [412]. However 98% of all glucose transported across the 
endothelial cell is not metabolised [413].  
There are 2 types of membrane associated carrier proteins responsible for glucose transport in 
eukaryotic cells; the sodium dependent transporters (SGLT) and the facilitated transporters 
known as GLUTs. Glucose transport into and across endothelial cells is principally brought 
about by facilitated glucose transport via GLUT. This has been mainly investigated in the 
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blood brain barrier in isolated animal cells and the process was found to be sodium 
independent and related to the concentration gradient across the membrane suggesting the 
GLUT facilitated transport is the predominant process [414]. Glucose transport out of the 
endothelial cell also seems to facilitated by GLUT with a distribution ratio of 1:4 between the 
luminal and abluminal membranes in bovine brain endothelium [415]. 
GLUT 1 is the most abundant glucose transporter present in endothelial cells and has been 
extensively studied in the blood brain barrier. GLUT 1 has also been found in human retinal 
endothelial cells [416], Human placental endothelium [417], Human testis microvessels [418] 
and Rat aorta endothelium [419]. 
GLUT 3 has been found on human placental microvessels [420], GLUT 4 on rat brain 
endothelium [421] and GLUT 5 on human brain endothelial cells, though this did not seem to 
have an effective glucose transport role [422]. 
GLUT 2 role in glucose sensing 
 When extracellular glucose concentrations rise the pancreatic beta cell transports glucose into 
the cell via the high turnover GLUT 2 transporter where it is then phosphorylated by 
glucokinase to glucose-6 phosphate. Oxidative and glycolytic metabolism of glucose raises the 
ATP/ADP ratio which causes depolarisation of the beta cell by the KATP channel, allows an 
influx of calcium and thus secretion of insulin. [411]. Cyclic AMP also plays an important role 
in potentiating this glucose dependent insulin secretion and acts in response to gut hormones 
(GLP-1, GIP and glucagon) [407]. 
 There is also a central glucose sensing mechanism in the brain which operates in a similar but 
inverse fashion to the pancreatic beta cell and its output is the release of counter-regulatory 
hormones to prevent hypoglycaemia. Thus this sensing system protects the glucose dependent 
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brain tissue from hypoglycaemia. The GLUT transporter involved in this process it not yet 
known, though GLUT 2 could be involved [433]. 
GLUT-3 is widespread in neuronal tissue and is likely to be the main transporter for nerves 
and brain [434]. 
GLUT-4 is the main insulin sensitive glucose transporter expressed in skeletal muscle, cardiac 
muscle and adipose tissue [408]. In adipocytes and skeletal muscle cells it is located in 
perinuclear vesicles which are translocated to the plasma membrane in the presence of insulin 
[435]. 
GLUT-5 has been found in intestinal tissues, kidney, skeletal muscle and adipocytes and its 
distribution is not affected by insulin. GLUT 6 & 8 are glucose transporters but are structurally 
different to GLUT 1-5 and do not respond to insulin [436]. GLUT 11 is only expressed in 
human cardiac and skeletal muscle. GLUT 6, 8 and 11 do not seem to be present in vascular 
endothelium [436]. 
Insulin Receptors 
Insulin receptors are present in virtually all human tissues though the concentration varies 
between 40 on erythrocytes to 200,000 on hepatocytes and adipose tissue [437]. 
The insulin receptor compromises 2 α subunits which are extramembraneous and act as the 
insulin-binding domains. There are also 2 intramembraneous β units. After binding with 
insulin tyrosine kinase is activated stimulating autophosphorylation in several regions of the β 
subunit [439]. These changes in the subunit activate the various intracellular insulin receptor 
substrate proteins which in turn trigger cytosolic post receptor cascades such as PI3K, Akt and 
MAP kinase which are responsible for the various metabolic actions of insulin within cell 
types [438]. 
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In skeletal muscle and adipose tissue the main actions of insulin are glucose transport and 
storage. In these tissues insulin achieves this by stimulating the translocation of the glucose 
transporter GLUT-4 from perinuclear storage vesicles to the cell membrane [438]. Insulin also 
slows the rate of internalisation of membrane GLUT-4 receptors therefore increasing the 
ability to import glucose in the presence of insulin [440]. Furthermore, insulin may aid 
docking of the GLUT-4 vesicles to the cellular membrane [440]. A similar process to increase 
cellular glucose transport takes place during exercise but it is not insulin dependent [436]. 
Interestingly insulin‘s role in overall body glucose handling is seemingly more important in 
some tissues than others and may go beyond glucose handling. Although skeletal muscle is 
responsible for 75% of glucose disposal, knockout mice bred with no insulin receptor in 
skeletal muscle have normal glucose tolerance [441]. However, mice with knockout of adipose 
insulin receptors have impaired glucose tolerance which originates from the muscle and liver 
[442], suggesting that metabolically, adipose tissue glucose handling may be more important. 
Neural brain specific receptor knockout mice show increased food intake, adiposity and 
insulin resistance [443]. 
Normal insulin secretion is a complex process which is influenced by a number of factors. 
Prevailing blood glucose concentration however is the most important factor influencing 
insulin release. Insulin is produced in a dose response curve that is sigmoidal in shape, giving 
large amounts of insulin secretion that correspond to usual post-prandial glucose 
concentrations. In this way, the pancreatic beta cell is able to maintain post-prandial blood 
glucose concentration within a tight range whatever the nutritional challenge. 
Once activated, insulin is released in a biphasic fashion with an initial rapid peak followed by 
a second, slowly rising peak. The clinical relevance of the first phase peak is unclear but the 
second phase response is directly related to the prevailing blood glucose concentration [405]. 
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Furthermore, exposure of the beta cell to chronically raised blood glucose concentrations 
primes its response to subsequent blood glucose concentrations, giving a greater insulin 
secretion for each given level of blood glucose. This increase in beta cell insulin sensitivity 
seems to be brought about by the over expression of hexokinase in relation to glucokinase. 
Hexokinase is a more potent enzyme giving a greater insulin secretion response. 
Insulin is then produced as the proinsulin molecule which is broken down intracellularly to 
give two chains of active insulin and C peptide which are secreted by exocytosis [403]. The 
latter can be used as a marker of insulin release. Insulin is secreted into the portal circulation 
and travels through to the liver where it reduces hepatogluconeogenesis and then enters the 
peripheral circulation to facilitate glucose disposal, particularly in adipose and skeletal muscle 
tissue. 
Insulin secretion in type 2 Diabetes 
Beta cell dysfunction is a key pathological process in the development of type 2 diabetes. In 
the prediabetes stage insulin secretion is actually enhanced as a compensation for reduced 
insulin sensitivity. However, in certain predisposed individuals progressive beta cell failure 
leads eventually to loss of glucose homeostasis. 
Beta cells in diabetes show loss of the first phase insulin secretion response, reduced insulin 
content [18] and reduced insulin mRNA expression [19, 20]. The insulin secretion response to 
the gut hormones is also attenuated as shown in the incretin effect.  Insulin secretion is also 
deranged, with a higher proportion of the less efficacious proinsulin released [21]. 
 The most important factor in beta cell dysfunction is a gradual loss of beta cell mass. This is 
supported by studies that have consistently found reduced beta cell mass in the pancreas of 
individuals with type 2 diabetes (up to 40%) in comparison to non-diabetic control subjects, 
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even in lean individuals [22,23,24].  Furthermore, in vivo studies have shown dynamic 
parameters of beta cell function to worsen over time and can be used to predict those 
individuals that progress from a prediabetes state to diabetes [25, 26]. In the Belfast Diet study 
[27], in individuals whose type 2 diabetes was controlled with diet alone and whose insulin 
sensitivity remained stable, markers of beta cell function closely predicted failure of diabetes 
treatment (diabetes progression). This also mirrors the data produced in the landmark study 
UKPDS which followed patients over 20 years and showed that irrespective of treatment type, 
plasma glucose concentrations deteriorated with time and this was closely followed by the 
beta cell function as measured by HOMA-B.  
Insulin Resistance and Diabetes 
The pathological processes that underpin insulin resistance are unclear, but a major role seems 
to be played by a delay in insulin delivery to the tissues responsible for glucose disposal [28].  
Skeletal muscle accounts for up to 80% of insulin-mediated glucose disposal in euglycaemic-
hyperinsulinaemic clamp studies in humans [29] and is the metabolic tissue with the capacity 
to vary rates of glucose disposal. Insulin stimulated suppression of gluconeogenesis in the 
liver is a rapid response to physiological (relatively low) levels of insulin [29] and furthermore 
its rate is similar between healthy and insulin resistant individuals [30], suggesting it does not 
play an extensive role in insulin resistance. 
Insulin delivery to the skeletal muscle is dependent upon muscle blood flow, the available 
microvascular exchange surface and trans-endothelial transport of insulin in the muscle 
capillary beds into the myocyte. Once at the myocyte, insulin stimulates storage of glucose as 
glycogen, thus regulating blood glucose. 
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Vasoactive actions of insulin 
Insulin has vasoactive actions in the metabolic capillary beds as well as metabolic actions and 
by doing so may facilitate its own delivery to the myocytes. At the level of the resistance 
vessels insulin can cause vasodilation so increasing overall limb blood flow [31] and can dilate 
terminal arterioles allowing for capillary bed recruitment, thus increasing the microvascular 
exchange surface. There have been studies that have showed a strong correlation between total 
limb blood flow and whole body glucose uptake [32] although these have not always been 
replicated, particularly in insulin resistant individuals [33]. At the level of the endothelium, 
insulin can act on the endothelial cell via its insulin receptor and stimulate several intracellular 
signalling pathways. There are 2 main pathways of post receptor signalling, PI3K and MAPK. 
(Figure 2) 
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Figure 2. Insulin signalling pathways in the endothelial cell. 
The PI 3K pathway is responsible for the metabolic actions of insulin in the skeletal muscle 
and adipose tissue and also has been shown to stimulate vasodilation via nitric oxide (NO) 
production in human umbilical vein endothelial cells [404,34]. In contrast, the MAPK 
pathway induces vasoconstriction via the potent vasoconstrictor endothelin -1. The MAPK 
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pathway also stimulates intracellular cytokine production and expression of cellular adhesion 
molecules, both of which are detrimental to endothelial function.  In healthy states the balance 
of these pathways favours vasodilation in response to insulin but in states of insulin resistance, 
insulin triggers the MAPK pathway and thus vasoconstriction [35] which may be why the 
insulin-mediated vasodilation phenomenon is absent or blunted in insulin resistant individuals. 
Many of the biochemical processes that typify diabetes push the balance of the insulin 
signalling in the endothelium towards the MAPK pathway. These include vascular 
inflammation, oxidative stress, hyperinsulinaemia, hyperglycaemia, and increased free fatty 
acids (FFA) [35]. This results in endothelial dysfunction which can lead to reduced glucose 
handling by the skeletal muscle and favours pro-atherogenic factors which, in larger vessels, 
may lead to early atherosclerosis. 
 Reducing the potential activators of the MAPK pathway may therefore serve to tackle insulin 
resistance. 
1.2 Traditional risk factors for cardiovascular disease 
As cardiovascular and cerebrovascular disease are responsible for 80% of diabetes related 
mortality [36], adequate treatment of the risk factors for vascular disease is given equal 
priority to blood glucose control in patients with diabetes. 
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There are long established risk factors for cardio and cerebrovascular disease which can be 
categorised into reversible and non reversible.  
 
Table 2: Reversible and non reversible risk factors for vascular disease 
Reversible Non Reversible 
LDL Cholesterol Age 
Blood pressure Gender 
Glycaemic control Family History 
Smoking  
 
Traditional risk factors such blood pressure, high serum LDL cholesterol and glycaemic 
control have been aggressively treated in numerous studies in those with diabetes [37,38] and 
have shown mortality and morbidity benefits. The land mark study which established the 
reversible link between glycaemic control and vascular (particularly micro) complications was 
the UKPDS [37] which ran for 20 years (1977-1997). 
Interventions addressing these reversible risk factors have produced reductions in the 
incidence of myocardial infarction and stroke in diabetes [5]. However, despite this 
cardiovascular complications of diabetes continue to cause significant morbidity and mortality 
[10]. 
 
1.3 Novel Risk factors  
The additional risk of coronary heart disease in people with diabetes cannot be explained in 
terms of the traditional risk factors mentioned above. [39, 40, 41]. 
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This suggests there are underlying processes prominent in diabetic complications, which as 
yet, remain untreated by ameliorating traditional risk factors. 
Many of the traditional risk factors share similar underlying biochemical processes such as 
oxidative stress, vascular inflammation and endothelial dysfunction which could explain their 
contribution to the complications of diabetes.  Further consideration shows these processes to 
be present even before the development of diabetes [42, 43, 44, 45] and they also seem to have 
a fundamental role in the pathogenesis of diabetic complications. (See figure 3) 
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Figure 3. Diagram to show the common soil hypothesis of the inter-relationship between oxidative 
stress, vascular inflammation and endothelial dysfunction in type 2 diabetes. The points at which 
garlic may be effective are marked with a G 
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1.3.1 Role of Oxidative Stress in Diabetes 
Free radicals are naturally created during biochemical processes, but usually these are 
metabolised harmlessly. Free radicals are molecules containing one or more unpaired electrons 
and as such have a high degree of reactivity. Free radicals derived from oxygen represent one 
of the most important radical species and are termed reactive oxygen species (ROS). 
Oxidative Stress results from an imbalance in the generation of ROS and the organism‘s 
ability to metabolise them. Thus oxidative stress can occur as a result of increased oxygen 
radical production or reduced antioxidant defence, or both.  
 
 
 
 
 
 
 
Figure 4: Pathways of reactive oxygen species production and clearance. 
Many studies have found markers of oxidative stress are increased in type 2 diabetes. An 
increase in superoxide levels has been found in hypertensive diabetes patients [46] and direct 
markers of oxidative stress have also been found to be raised in diabetes [47, 48]. In vivo 
studies suggest endothelial cells cultured in hyperglycaemic media show increased superoxide 
production and an upregulation of antioxidant genes such as those coding for glutathione 
peroxidase 1, peroxiredoxin 6 and thioredoxin 2 [49, 50]. Furthermore clinical studies have 
shown that fluctuations in blood glucose in diabetes act as a strong predictor of oxidative 
stress levels [51, 52, 53]. 
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During oxidative stress, the resultant excess of free radicals leads to damage of cell 
components, particularly lipids, proteins and DNA. This can manifest itself in the 
complications of diabetes as described below. There is also stimulation of numerous 
intracellular biochemical pathways, many of which perpetuate oxidative stress, therefore 
initiating a downward spiral. 
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1.3.2 Potential sources of ROS production in Diabetes 
Oxidative Phosphorylation 
Between 0.4 and 4% of mitochondrial oxidative phosphorylation in normal cells produces 
ROS [54] but this figure is increased in diabetes. It has been suggested from animal and in 
vitro studies that hyperglycaemia and a deficiency of uncoupling proteins both act on the 
mitochondria to increase intracellular ROS production [55, 56]. 
However, hyperglyceamia induces ROS production even in cells lacking mitochondria [57]. 
These cells are thought to be subject to glucose autoxidation, a reaction of glucose with 
molecular oxygen in the presence of transition metals to give hydrogen peroxide, superoxide 
ions and hydroxyl radicals, one of the most reactive ROS [58]. Chelators of transition metals 
have been used in diabetic models to prevent superoxide production in these cells [59]. 
NADPH oxidase 
NADPH oxidase is a membrane-associated enzyme present in many cells and in normal cells 
produces small numbers of ROS but its activity is increased in disease states and diabetes. 
Superoxide production by NADPH has been shown to be increased in aortic endothelial cells 
exposed to a high glucose environment [60] and in the renal cortex of diabetic rats [61]. 
Nitric Oxide Synthase 
Another potential source of ROS is Nitric Oxide Synthase (NOS). Nitric oxide is an important 
modulator of vascular function and its production from L-arginine is catalysed by endothelium 
derived NOS (eNOS). eNOS is inducible and its production is upregulated in diabetes in 
human [62] and animal models [63,64]. In the pro-oxidant state of diabetes, the increased 
levels of NO react with ROS to give peroxynitrite, a highly reactive oxidant [65]. 
Furthermore, the hyperglycaemic state favours peroxynitrite to react with NOS, which 
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uncouples the enzyme encouraging it to produce superoxide anions rather than NO [66]. In 
this way ROS not only quench NO, which has antioxidant properties, but also prevent NOS 
replenishing NO levels. This lack of NO has been suggested to directly affect endothelial 
function [67]. 
Advanced Glycation End Products 
Chronic exposure of proteins, DNA and lipids to high glucose causes the spontaneous 
formation of a glycated Amadori product. These products can undergo further reactions to 
form advanced glycation end products (AGEP), which are almost universally found in diabetic 
tissues. This process is accelerated by ROS [68]. AGEPs have been implicated in the 
formation of diabetic complications, both directly and indirectly [69]. AGEPs can also 
generate ROS through the Malliard reaction and through their interaction with RAGE 
receptors on the endothelial cell membrane [70], which increases ROS production by NADPH 
oxidase [71]. 
Increased Polyol Pathway 
At normal glucose concentrations the activity of aldose reductase in the Polyol Pathway 
accounts for only a small percentage of glucose metabolism.  
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Figure 5: Polyol pathway of glucose metabolism 
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However, in the hyperglycaemic state much more glucose is put through the pathway leading 
to increased intracellular sorbitol and reduced NADPH concentrations. It has been postulated 
that increased intracellular sorbitol may increase oxidative stress and the polyol pathway itself 
consumes NADPH therefore reducing the cells ability to produce glutathione and so reducing 
cellular anti oxidant defence [72]. 
1.3.3 Reduced antioxidant defence in diabetes 
Oxidative stress is potentiated in diabetes by the inhibition of antioxidant enzymes and 
depletion of antioxidants themselves.  
Vitamins E and C are major antioxidants in the plasma and the cytosol of many cells and they 
act synergistically. The amounts of these vitamins in the plasma has been shown to be reduced 
in diabetes [73,74] and are inversely proportional to the presence of diabetic complications 
[75] and the duration of type 2 diabetes [73]. 
Glutathione (GSH) is the principal thiol intracellular antioxidant and as such the relative 
amount of intracellular reduced and oxidised GSH is a measure of the cells redox status. 
Decreased intracellular concentrations of reduced GSH have been found in numerous cell 
types in diabetes [73, 75, 76] and has been found to be inversely proportional to severity of 
diabetic complications [77] and the duration of diabetes [73] and has shown a strong negative 
correlation with plasma HbA1c levels [78]. 
The principal antioxidant enzymes involved in antioxidant defence are Glutathione 
peroxidase, Catalase and Superoxide Dismutase [79, 58]. The activity of these enzymes has 
been shown to be reduced in diabetes [80, 81] and supplementations of their actions have been 
therapeutic targets with variable success [82, 83, 84, 85]. 
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1.3.4 Oxidative stress and complications of diabetes  
There is a large body of evidence suggesting a link between oxidative stress and both micro 
and macrovascular diabetic complications. Plasma concentrations of antioxidants are reduced 
in those with diabetic complications [47, 86, 75]. The risk of diabetic complications is not 
distributed equally among diabetic patients with similar hyperglycaemic exposure. Some 
individuals seem to have innate protection against developing complications. This could be 
explained by differences in the genetically determined cellular redox status of individuals [87]. 
Similarly, the redox status of particular organs make them more susceptible to hyperglycaemic 
damage, including the beta cell which has a physiologically low level of oxidant defence [88]. 
Increased oxidative stress also causes increased vascular inflammation and consequent 
endothelial dysfunction suggesting oxidative status could play a pivotal role in the 
pathogenesis of diabetic complications and even diabetes per se. [89, 58, 90].  
Much of the evidence for a role of oxidative stress in microvascular complications is in vitro 
or indirect. Serum AGEP concentrations are increased in diabetic patients with retinopathy 
and the concentrations are correlated positively with the severity of the retinopathy [91, 92]. 
Use of AGEP inhibitors in diabetic rats reduced pericyte apoptosis and abnormal endothelial 
cell proliferation, both early changes in the development of diabetic retinopathy [93]. 
AGEP formation has been implicated in both neuropathy and nephropathy and the use of 
AGEP inhibitors has prevented early changes in both these complications [94, 95, 96, 93]. 
Antioxidants such as N acetyl cysteine [97], -lipoic acid [98] and L propyl carnithine [99] 
have all had beneficial effects in animal models. 
Macrovascular complications, principally atherosclerosis, start even before the onset of 
diabetes and there is strong evidence that that oxidative stress plays a role in this process, 
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often via its effect upon endothelial function. Some clinically used medications have been 
shown to have intracellular antioxidant properties such as TZDs (thiazolidinediones) [100], 
Statins [101], ACEI [102] and Beta Blockers [103] and there is evidence that all of these 
improve cardiovascular outcome in diabetes [104, 105, 38, 106]. 
Epidemiological studies have suggested that individuals with a high intake of antioxidant 
vitamins have a lower than average risk of cardiovascular disease [393, 394, 395]. However, 
large studies using antioxidant supplementation have been disappointing in improving 
cardiovascular outcomes [107, 108, 109, 38, 110, 111, 112]. This may be due to single 
antioxidants being used and, given that naturally occurring antioxidants often work 
synergistically, it may be that using a cocktail of antioxidants could give a more positive 
finding. 
1.3.5 Role of vascular inflammation in diabetes 
The aetiology of diabetes has been suggested to be linked to a state of low-grade systemic 
inflammation [113,114, 115, 116]. This has been supported by numerous studies showing an 
increase in inflammatory markers in those with diabetes [117,118, 119] and epidemiological 
data suggests chronically raised inflammatory markers can predict those who will go on to 
develop diabetes [113]. High dose salicylates and anti-inflammatories have also been used to 
successfully lower glucose concentrations [120, 121]. 
The source of this inflammatory state in diabetes is probably multi-factorial. Oxidative stress 
can trigger intracellular signalling pathways, which stimulate production of a proinflammatory 
milieu including NF-B [122, 123], JNK/SAPK [124] and Protein Kinase C [125, 126, 127]. 
These stimulate inflammation by gene transcription [128], growth factor [129] and cytokine 
production and may induce insulin resistance by disrupting intracellular insulin signalling 
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pathways [130, 131]. Furthermore, hyperglycaemia itself is pro inflammatory [127] and 
central obesity, which often coexists with diabetes, is thought to induce inflammation by 
reducing adiponectin (an insulin sensitizer) [132, 133] and production of inflammatory 
cytokines [134, 113]. 
Markers of inflammation such as high sensitivity CRP (HsCRP), interleukin 6 (IL-6) [135] 
and tumour necrosis factor  (TNF-) have all been positively correlated with insulin 
resistance in people without diabetes [135, 136] and have been found to be high in patients 
with diabetes [137, 113] and have been associated with diabetes complications [138]. This has 
been supported by animal studies suggesting IL-6 modifies glucose stimulated insulin release 
from pancreatic  cells in rats and reduces insulin-stimulated hepatocyte glycogen production 
in vitro [139]. Suggested consequences of this chronic inflammatory process include the effect 
of cytokines on the liver where they increase the synthesis of acute phase proteins [140, 141]. 
Acute phase proteins have been shown to be raised in diabetes [142, 143, 144] and, by means 
of their actions in the liver, give the typical atherogenic lipid profile of type 2 diabetes [145]. 
Furthermore, they have been directly implicated in the pathogenesis of atherosclerotic plaques 
[117, 146,147,148]. Insulin is also noted to reduce acute phase protein synthesis and the 
presence of insulin resistance reduces this effect [149]. 
1.3.6 Vascular inflammation and complications of diabetes 
Atherosclerosis, as with diabetes, has been shown to be an inflammation driven process [150]. 
Elevated HsCRP, TNF α, IL-6, ICAM-1 and fibrinogen have been found to be independent 
predictors of cardiovascular risk [148, 151, 152], Indeed, HsCRP has been shown to be a more 
potent predictor of cardiovascular risk than LDL cholesterol [153]. Many of these 
inflammatory markers have also been linked to insulin resistance suggesting a common basis 
[154, 155, 156]. The endothelium responds to both hyperglycaemia and hyperlipidaemia with 
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an inflammatory response and this pushes the normal endothelial equilibrium in a pro-
atherogenic direction [157, 158]. 
Several well established pharmaceutical agents have been found to have anti-inflammatory 
properties. Large clinical trials with agents such as statins (cholesterol lowering agent) and 
angiotensin converting enzyme inhibitors (ACEIs – anti-hypertensives) and TZDs 
(hypoglycaemic agents), have shown reductions in levels of circulating proinflammatory 
markers [159, 160, 161], reductions in insulin resistance [162, 163] and reduced LDL levels 
[164], and may even delay the development of diabetes in high risk individuals [165]. 
1.3.7 Role of endothelial dysfunction in diabetes 
Definition 
The endothelium is a single cell layer lining the blood vessels, which acts as the first line of 
vascular defence. The endothelium maintains vessel function by regulation of tone, 
inflammation, growth and homeostasis. It is a metabolically active organ whose surface area 
would cover the surface of a football pitch and whose weight would be similar to that of the 
liver [166]. The endothelium modulates vascular permeability and maintains the balance of 
coagulant and fibrinolytic mediators. It also has an anti-inflammatory role within the vessel 
wall including control of leucocyte adhesion and migration. It also plays a vital role in the 
actions of other cells in the vasculature such as smooth muscle, platelets, leucocytes and large 
artery macrophages. 
Endothelial dysfunction is the inability of the endothelium to maintain vascular function and is 
multifaceted. 
Endothelial cells exposed to chronic high glucose concentrations exhibit increased cell 
apoptosis [167], increased extracellular matrix production and increased pro-coagulant protein 
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production [168]. Endothelial function can also be impaired by obesity, hypertension, 
increased triglyceride, reduced HDL, hyperinsulinaemia and low-grade inflammation, many of 
which are present in type 2 diabetes [169]. However, endothelial dysfunction is also present in 
individuals before the diagnosis of diabetes, [170] leading to the speculation that endothelial 
dysfunction may play an important role in the insulin resistance that typifies type 2 diabetes. 
1.3.8 Endothelial dysfunction as a source of insulin resistance 
Insulin resistance is the pathological process that underpins type 2 diabetes and many 
associated conditions such as obesity, hypertension and hyperlipidaemia. In an insulin-
sensitive individual insulin acts as a vasodilator in metabolically active tissues such as adipose 
tissue, liver and skeletal muscle. After a meal, physiological levels of insulin recruit capillary 
beds and insulin mediated vasodilation increases blood volume in skeletal muscle and thus 
increases glucose and insulin delivery to the appropriate tissues maximizing glucose disposal. 
It has been suggested that endothelial function has different effects in different vascular beds 
[79]. Large vessel endothelial dysfunction is a precursor of the accelerated atherosclerosis 
seen in those with diabetes [171, 172]. However, endothelial dysfunction in metabolically 
active capillary beds, such as skeletal muscle, may play an important role in insulin action and 
glucose handling [173, 174] (see vasoactive actions of insulin). 
The endothelium is a target for insulin action and is vital for insulin delivery to the tissues. 
Insulin is a vasodilator and its presence increases blood flow in skeletal muscle capillary beds, 
even when overall limb blood flow is not affected [175]. In insulin resistant skeletal muscle, 
capillarisation has been proved to be reduced [176]. Both of those pathophysiologies would 
contribute to reduced glucose disposal and increase insulin resistance.  Mice that are 
homozygous null for the eNOS gene are also found to be insulin resistant [177]. The 
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endothelium also acts as a barrier to insulin reaching the interstitium [174] and the transport of 
this molecule across the endothelium is delayed in insulin resistant individuals [173]. This 
seems to be particularly important in fluctuations of blood glucose suggesting that a delay in 
insulin delivery to the glucose handling tissues may be important in controlling 
hyperglycaemia. 
1.3.9 Endothelial dysfunction and complications of diabetes 
In diabetic retinopathy there is hyperpermeability and thickening of the basement membrane 
and eventually microthrombosis of the retinal microvasculature [178]. Here there is evidence 
of increased cell apoptosis [179], increased growth factors [180], and increased endothelin-1 
secretion [181] all suggesting underlying endothelial dysfunction. 
There is also evidence of microvascular endothelial dysfunction in diabetic nephropathy, again 
with an increase of apoptosis [97], increased growth factors [182] and impaired extracellular 
matrix turnover [183]. These give the hallmark pathological changes of diabetic nephropathy 
of basement membrane thickening and mesangial cell expansion. 
Similar changes have also been reported in the microvasculature surrounding nerves involved 
in diabetic neuropathy [184] with a suggestion of endoneurial hypoperfusion. However, the 
link between endothelial dysfunction and diabetic neuropathy is less clear. 
Atherosclerosis is a disease of the large vessels although endothelial dysfunction is thought to 
be a pivotal trigger in its pathogenesis [185, 186]. However, generalised endothelial 
dysfunction may play a part at distant sites. The small vessels represent a much larger surface 
area and synthetic capacity than the large vessels and changes at this level could influence 
pathology elsewhere [187]. 
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Loss of endothelial lipoprotein lipase action in the small vessels increases the exposure of 
large vessels to pro-atherogenic lipid particles [188] and these small LDL particles are also 
toxic to endothelial cells [189] propagating endothelial dysfunction. Changes in the 
extracellular matrix in the large vessels as a result of endothelial dysfunction increase 
retention of these particles, [190] encouraging atherosclerosis. 
It has also been suggested that endothelial dysfunction within adipose tissue prevents adequate 
insulin delivery and thus increases lipolysis and subsequent release of free fatty acids (FFA). 
FFA‘s have been shown to impair endothelial dependant vasodilation [191], increase insulin 
resistance [192] and effect changes in the extracellular matrix that promote LDL retention 
[193]. 
It has also been suggested that loss of endothelium dependant vasodilation of the small vessels 
may contribute to the systemic hypertension [187] that forms part of the common pathway to 
the pathogenesis of atherosclerosis in type 2 diabetes. 
1.4 The Common Soil Hypothesis of diabetes; The relationship between insulin 
resistance, endothelial function, oxidative stress and vascular inflammation 
The precise pathophysiology of the insulin resistance and beta cell dysfunction that underlies 
type 2 diabetes is uncertain. Furthermore, the precise pathophysiology of the vascular disease 
that makes up the majority of diabetes mortality is also unclear and is incompletely addressed 
by treatment of traditional risk factors.  It is clear that diabetes and other pro-atherogenic 
states, such as hypertension and obesity, share an upscaling of oxidative stress, endothelial 
dysfunction and inflammation. Increasingly it is being suggested that these processes are inter-
related and synergistic [51, 156, 194,195,196,197, 198]. (See Figure 3) 
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In individuals with a genotype which impairs their ability to cope with such biochemical 
stresses, a pro-oxidant and pro-inflammatory insult (usually obesity) increases the cells 
exposure to oxidative stress and an increased inflammatory load. The result of this insult is 
permanent damage to DNA, proteins and lipids and triggering of further signalling pathways 
which perpetuate the oxidative stress and inflammation and create a cycle which propagates 
the initial biochemical insult [195,199]. 
 In certain, more susceptible tissues, this oxidative stress and inflammatory load, results in 
dysfunction and loss of homeostasis [200,201,202]. These tissues include the pancreas and the 
vascular endothelium. 
The pancreatic beta cells are low in indigenous oxidant defence enzymes such as SOD, 
glutathione peroxidase and catalase, as are endothelial cells. In the face of oxidative stress this 
predisposes to beta cell failure [128, 203, 204,205], a preliminary pathological stage of 
diabetes.  
 In the endothelium, oxidative stress and excess inflammation result in endothelial 
dysfunction. In the metabolic capillary beds such as skeletal muscle, this can affect delivery of 
insulin to metabolic tissues and thus blunt its glucose handling effects and subsequently create 
insulin resistance [206, 207, 208]. Moreover, oxidative stress and inflammation can interrupt 
insulin dependent intracellular signalling pathways, directly affecting the ability of insulin to 
handle glucose in skeletal muscle [208].Together these processes eventually lead to persistent 
hyperglycaemia which in itself perpetuates oxidative stress and inflammation [201] and so the 
cycle continues. 
In the larger vessels, adequate endothelial function is necessary to protect against 
atherosclerosis and therefore the synergistic interaction of oxidative stress and inflammation 
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create endothelial dysfunction early in the course of diabetes and subsequently predispose an 
individual to early vascular complications. 
If these processes are inter-related and fundamental to the pathophysiology and vascular 
behaviour in diabetes then they would make attractive targets for potential intervention. One 
potential therapeutic strategy would be the use of garlic given that there is evidence suggesting 
garlic may have potent anti-inflammatory and anti-oxidant properties. 
1.5 Garlic 
1.5.1 Medicinal history of garlic 
Garlic has been used as a medicinal product throughout antiquity and is currently one of the 
most common alternative medicines taken by those with diabetes [209]. Use of garlic for 
infections and ―treating growths‖ was documented by the ancient Egyptians in the period 
1550-200BC [210]. The Chinese also used garlic for respiratory and digestive complaints in a 
similar era [211]. Later the ancient Indians and Ancient Greeks both recommended garlic for 
heart disease and arthritis and Hippocrates himself, the father of medicine, used garlic for 
pulmonary complaints and as a purgative. The Romans used garlic for ―cleansing the arteries‖ 
[212]. It is intriguing that cultures that rarely came in to contact, shared similar views on garlic 
as a medicinal product. Garlic has been found to have anticancer, antimicrobial, antifungal and 
cardiovascular protective effects.  
More recently, medicinal properties of garlic have been exposed to scientific scrutiny with 
mixed results [213, 214, 215, 216]. However, there is a growing body of evidence, in vitro and 
in vivo, suggesting garlic has antioxidant and anti-inflammatory properties [217, 218, 219, 
220, 221]. 
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1.5.2 Active ingredients and metabolism of garlic 
Chemistry/Preparations 
Garlic is a member of the allium family along with onions and shallots. The main ingredients 
within garlic that are thought to be responsible for its antioxidant effects are the sulphur 
compounds, though steroid saponins have also been implicated [222]. 
Garlic in its natural state contains very few of the active sulphur compounds that are found in 
its prepared state. Instead, it contains storage compounds termed S allyl L cysteine 
sulphoxides, mainly in the form of alliin. Upon cutting or maceration, enzymes (alliinase) 
within garlic tissue break these compounds down to volatile organosulphur products which 
give garlic the familiar smell and taste. The principal initial product of alliin is allicin. 
The first products to be produced upon activation of alliinase are sulphenic acids and 
thiosulphates. These are the precursors to many other compounds, the precise nature and 
balance of which are determined by the environmental conditions. Block et al [223] 
characterised the origin of these compounds as 
1. Chemicals derived from cutting or maceration of garlic at room temperature 
2. Decomposition products derived from thiosulphates at room temperature. 
These change with time. 
3. Oil components – chemicals derived from vigorous preparation techniques such 
as steam distillation 
Up to 50 of these products have so far been identified [224].  It is these products that have 
been implicated as the bioactive components of garlic. 
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Metabolism of garlic 
Despite a multitude of studies of studies examining the in vivo actions of garlic, little is known 
about the metabolism of garlic or the component organosulphur compounds.  
Alliin itself is not metabolised upon ingestion [225], presumably due to the inactivation of 
alliinase in the acidic environment of the stomach [226]. Alliinase activity is also reduced by 
cooking [227]. 
Allicin when added to blood is quickly converted to allyl mercaptan, which is not present in 
blood or urine in subjects that have ingested garlic [228], suggesting further metabolism takes 
place. This also suggests that allicin plays no meaningful role in any medicinal actions of 
garlic. [222,229].  
The main volatile metabolite detected after ingestion of garlic is allyl methyl sulphide (AMS) 
[230], detected on the exhaled breath of subjects. The amount of AMS detected has also been 
found to relate to the amount of raw garlic ingested [228]. 
Davenport et al [231] and Germain [232] found oxidised forms of AMS in the urine; allyl 
methyl sulphoxides (AMSO) and allyl methyl sulphone (AMSO2) suggesting the pathway of 
metabolism may be as suggested in figure 6. 
Figure 6: Proposed metabolism of Allicin [Adapted from 229]. 
 
 
 
A comprehensive understanding of the metabolism of garlic in humans remains elusive. Many 
of these studies were performed on rodents and as such should be extrapolated to human 
Allicin   Allyl Mercaptan    (AMS)   AMSO   AMSO2 
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subjects with caution. Those conducted in human subjects concentrated on breath studies 
which will only detect volatile metabolites. Analysis of blood metabolites may be a more 
informative and complete measure of bioavailability. 
Different preparations of garlic 
There are numerous preparations of garlic available and due to the nature of their preparation 
the constituent compounds can be numerous and vary widely (figure 7). This makes 
interpretation of studies using garlic compounds challenging since they may be comparing 
different constituent compounds. 
Whole garlic tissue 
(S-allyl L cysteine sulphoxides) 
 
  Alliinase 
Sulphenic Acids (intermediates) 
 
 
Thiosulphonates 
 
 Tissue damage  100°C     +Cysteine 
 
Volatiles   Oil distillates   Aged Extracts 
(disulphides)   (mixed polysulphides) (Thiol derivatives) 
 Figure 7. Processing of garlic gives different end products (adapted from [222] and 
[224])
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Table 3: Major constituents of widely used garlic preparations 
Garlic Preparation Major constituents 
Garlic Essential oil 
Oil soluble sulphur compounds; diallyl 
suphides (DAS), diallyl disulphide (DADS), 
diallyl trisulfide (DATS), 1,2-epithiopropane, 
vinyldithiins. 
Garlic Macerate oil 
Oil soluble sulphur compounds; diallyl 
suphides (DAS), diallyl disulphide (DADS), 
diallyl trisulfide (DATS), 1,2-epithiopropane, 
vinyldithiins 
Garlic Powder 
g-glutamyl-S-allyl-L-cysteines, S-allyl-L-
cysteine sulphoxides, small amounts DAS, 
DADS 
Garlic Extracts 
S-Allyl Cysteine (SAC), S-Allyl 
mercaptocysteine (SAMC), small amounts 
DAS, DADS 
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Many products are processed with a view to maximising the bioavailability of the active 
ingredients and reducing the harsh taste and smell. However, the true bioactive compounds 
within garlic remain unclear and controversial. 
Garlic oil contains only oil soluble sulphur compounds but not water soluble compounds or 
allicin. 
 Garlic powder is produced from cloves of garlic which are pulverised into powder. Garlic 
powder contains alliin and small amounts of oil soluble sulphur compounds, very similar to 
that of raw garlic. 
Distilled garlic is prepared by steam distilling whole garlic cloves ground in water. This gives 
small amounts of essential oils which are then mixed with soya oil. The main active 
ingredients are oil-soluble compounds such as diallyl sulphide (DAS) and diallyl disulfide 
(DADS) 
Aged Garlic Extract (AGE) is prepared by storing sliced raw garlic in 15-20% ethanol solution 
for 20 months at room temperature. Almost all of the allicin is degraded over this period. The 
extraction process is thought to encourage the development of stable, bioavailable products 
such as S allylcysteine (SAC), S allyl mercaptocysteine (SAMC), allixin and selenium [233] 
all of which have been shown to exhibit anti oxidant properties in their own right [234] and 
have been suggested to be more potent than fresh garlic [235,236]. There are also small 
amounts of oil soluble compounds (DAS, DADS) and saponins [233]. 
The largest constituent of AGE is SAC followed by SAMC. Studies on the metabolism of 
these substances suggest they have shown that SAC is present in blood after ingestion and its 
concentration is related to the amount ingested [237]. 
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1.5.3 Garlic as a therapeutic agent 
Any research study that aims to study the effects of garlic needs to recognise the uncertainties 
surrounding the bioactive constituents of garlic-containing preparations. Therefore garlic 
preparations studied should satisfy the following criteria: 
1. Well standardised constituents  
2. Evidence of in vitro antioxidant efficacy 
3. Evidence of antioxidant effect in vivo in similar population to our own 
4. Evidence of a feasible mechanism of action, with identified bioactive, bioavailable 
constituents 
5. Evidence of safety 
AGE represents the preparation with the largest body of evidence satisfying the above criteria 
[222, 233, 235, 237, 246, 247]. The evidence was largely restricted to cell lines and in-vitro 
studies or small in vivo studies and often performed by the manufacturers‘ own employees. 
However, this criticism can equally be levelled at all other preparations of garlic. 
AGE is prepared by storing sliced raw garlic in 15-20% ethanol solution for 20 months at 
room temperature. The extraction process maximises the content of stable water soluble 
organosulphur compounds, largest amongst which are S allyl cysteine (SAC) and S allyl 
mercaptocysteine (SAMC).This process, according to the manufacturers, reduces the harsh 
taste and odour of garlic and gives a standardised preparation (205g/l dry weight of the active 
ingredients) The extract is produced by Wakunaga Pharmaceuticals, California, USA and 
marketed as Kyolic. 
Its constituents have been identified [233] and the pharmacokinetics and bioavailability 
investigated [237]. AGE and its constituents have been shown to have antioxidant effects in 
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vitro [238, 239, 240, 241] and in vivo [242, 243]. It has also shown anti-inflammatory effects 
in vitro [244] and its safety has been investigated [245, 246]. There is also some evidence that 
its antioxidant capabilities are greater than other garlic preparations but this is based on 
unpublished data from the manufacturer [247]. 
1.5.4 Garlic and oxidative stress 
There is in vitro evidence that garlic reduces oxidative stress, both in relevant cell lines 
[248,249,250] and in diabetic animal models [251, 252]. 
Lee et al [251] used db/db (+/+) C57BL/KsL mice, a genetically modified diabetic model that 
mimics the insulin resistance, hyperinsulinaemia and pancreatic β cell failure seen in human 
diabetes. This study investigated the effects of diet supplementation of aged black garlic on 
lipid peroxidation (TBARS) and the effect on antioxidant enzyme activity in the liver and 
found that Aged black garlic reduced hepatic TBARS and increased antioxidant enzyme 
activity. However, this study used very young mice (3 weeks) and these models do not reach 
the peak of hyperglycaemia until 3-4 months [253]. Moreover, measuring antioxidant activity 
in the liver is likely to only be relevant to fasting hyperglycaemia. This study also employed 
high doses of garlic extract (5% of diet) and for a relatively long period of time (7 weeks). 
Kanth et al [252] investigated the effect of garlic on oxidative stress markers (glutathione and 
antioxidant enzymes) in hepatic and intestinal tissues in a streptozocin induced diabetes model 
in Wistar rats and found garlic extract to be protective against oxidative stress. This study used 
large doses (500mg/kg), investigated tissue specific antioxidant concentrations rather than 
systemic concentrations and the streptozocin diabetic rat model is more synonymous with type 
1 than type 2 diabetes in humans. 
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Garlic has been shown to have beneficial effects upon markers of oxidative stress in human 
subjects [200, 254, 255, 256] but these studies have been small (10-50 subjects), of varying 
duration (2weeks -6 months) and have used numerous preparations and doses of garlic and 
different measurements of oxidative stress. They have also all used very different cohorts of 
subjects, which may derive their oxidative stress from different mechanisms. Furthermore, 
none of these studies included subjects with diabetes. 
 AGE has been shown to be an effective antioxidant both in vitro and in clinical studies [237, 
239, 241]. Thus, garlic may have the potential to be an effective anti-oxidant agent in diabetes. 
AGE has been shown to have free radical scavenging properties and also to increase 
antioxidant defence [239] in vitro. These effects have been shown in endothelial cells [248], 
liver cells [249] and erythrocytes [250], all of which are potential targets of oxidative stress in 
diabetes. However, caution must be exercised when extrapolating these results to human 
subjects since the bioavailability of AGE may be very different in vivo, as may the oxidative 
process that is being replicated in the laboratory.  
AGE has also been found to have antioxidant properties in a small number of clinical studies. 
Dillon et al [243] compared the antioxidant action of AGE in 20 smokers and non smokers 
without diabetes. This study used 2 weeks treatment with 5ml/day of AGE and then had a 2 
week washout period. In the smoking group, 2 weeks of treatment with AGE reduced urinary 
and plasma levels of the prostaglandin F2-isoprostane 8-iso-prostaglandin, a marker of lipid 
peroxidation, by 48% and 35% respectively. The urinary and plasma levels of F2-isoprostane 
8-iso-prostaglandin were also reduced in the non-smoking group and the levels in both groups 
returned to baseline after a 2 week washout period. These subjects were otherwise healthy and 
not taking any medication. 
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1.5.5 Garlic and endothelial function 
There is limited data examining the effect of garlic on endothelial function. Garlic has 
successfully improved nitric oxide mediated vasodilation in isolated rat pulmonary arteries 
[257] and in the isolated aortic rings in rats with streptozocin-induced diabetes [258]. Kim-
Park et al [257] exposed isolated rat pulmonary arteries to garlic extract in experimental 
circumstances. This study found that garlic had the ability to protect against hypoxia induced 
vasoconstriction and the effects seemed to be endothelium-dependent. Baluchnejadmojarad et 
al [258] showed similar results in isolated aortic rings in a rodent diabetic model. However, 
these results should be considered with caution. Both these studies used isolated tissue which 
may react very differently in vitro and used hypoxic vasoconstriction as a marker of vascular 
reactivity which is a different process than that involved in diabetic vascular reactivity. 
Furthermore, Kim-Park‘s study treated the pulmonary arteries directly with large doses of 
garlic, a process which is unlikely to happen in vivo. Baluchnejadmojarad‘s study used a 
streptozocin-induced diabetes model and the garlic extract was given to the rats before aorta 
isolation, making this more physiological, although the garlic extract was given via the 
peritoneum which is not physiological. However, the streptozocin model is suitable for 
investigating the effects of hyperglycaemia only and may not suitably mimic the pathological 
processes in type 2 diabetes. 
Not all rodent studies have been supportive of garlic‘s potential endothelial action. Sun et al 
[259] fed rats relatively large doses of raw garlic, boiled garlic and aged garlic and then 
investigated the vascular reactivity of isolated coronary arteries to vasoconstrictors or 
relaxants. This study only showed benefit from raw garlic and the authors suggest this may be 
due to the lack of allicin content in the other garlic preparations. However, it is known allicin 
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is not bioavailable in humans after ingestion of garlic. Many of the limitations mentioned 
previously are also applicable to this study. 
Clinical studies using AGE to improve the vasomotor element of endothelial function have 
been limited in number, though AGE remains the most investigated garlic preparation. Weiss 
et al [260] studied flow mediated dilatation in the forearm after acute homocysteinaemia. After 
treatment with AGE, a 66% increase in forearm blood flow was detected.  
Budoff et al [242] also studied the effect of AGE upon endothelial function in 65 subjects with 
moderate cardiovascular risk over 1 year. Williams et al [261] studied the effect of AGE on 
endothelial function in 15 subjects with coronary artery disease over 2 weeks. Both of these 
studies showed improvement in endothelial function following treatment with AGE.  
1.5.6 Garlic and inflammation 
Inflammation has been established as a key process in the development and progression of 
atherosclerosis. Normal endothelial cells resist leucocyte adhesion, however once inflamed 
(secondary to oxidative stress) endothelial cells express adhesion molecules (such as Vascular 
Cell Adhesion Molecule, VCAM-1 and Intercellular adhesion molecule, ICAM- 1). Intima-
derived chemo attractants (such as Monocyte chemo attractant protein-1, MCP-1) then 
facilitate the movement of macrophages and T cells in to the intima. These cells stimulate a 
local inflammatory response with an increase in cytokines such as interleukin 6, CRP and 
TNF- α. 
This inflammatory process stimulates proliferation of vascular smooth muscle cells and the 
production of proteases which progress the development of the atherosclerotic plaque and 
eventually can lead to its rupture [262]. 
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Many of the molecules involved in this process have been used as biomarkers for 
atherosclerotic progression. Indeed, several of these markers (particularly CRP) have been 
shown to have strong predictive value for future coronary artery disease, even in apparently 
healthy individuals [263, 264, 265]. However, it is questioned whether these are markers of 
systemic inflammation or mediators of the atherosclerotic process [266] and it is uncertain 
whether reduction of these circulating molecules will reap clinical benefits. These molecules 
are not specific to vascular inflammation and circulate in plasma in response to many causes 
of inflammation [267]. CRP, for example, is mainly produced in the liver following cytokine 
stimulation and therefore is a systemic acute phase protein. In vitro evidence of the direct role 
of CRP has been inconsistent and has often used supraphysiological doses [268]. However, 
more recent in vivo studies have shown CRP to be produced more locally in the smooth 
muscle cells underlying atherosclerotic plaques [269] and endothelial cells of normal and 
diseased coronary arteries [270]. Furthermore, CRP levels have also been associated with 
fragility of atherosclerotic plaques [271].  
Ide et al studied the effect of AGE on LDL oxidation but also on TNF-α-induced NF κB 
activation, a key precursor to the intracellular inflammatory process. Ide suggested endothelial 
cells cultured in S allylcysteine (a key antioxidant in AGE) had 60% less NF κβ activation 
than those without S allylcysteine [244].  
Hui et al studied the anti-inflammatory effect of S-Allyl-L-cysteine Sulphoxides (ACSO), a 
water soluble garlic derived compound on the human umbilical vein endothelial cells. Hui and 
colleagues showed a reduction in several TNF-α mediated intracellular pathways [221]. 
Clinical studies have largely failed to replicate these in vitro results. Van doorn et al [273] 
studied the effect of garlic powder upon 90 overweight smokers at a dose of 2.1g/day over a 
period of 3 months. This study showed garlic powder had no effect on plasma CRP or TNF-α 
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levels in comparison to placebo. In the same study, Atorvastatin showed significant reductions 
in all plasma inflammatory markers. Williams et al [261] also showed no effect of AGE in 
their study in individuals with coronary artery disease. Budoff et al [242] did show an 
improvement is plasma CRP levels however this was using a combination of antioxidants 
including AGE. 
1.5.7 Garlic and insulin resistance 
There is very little evidence for employing garlic to treat insulin resistance. Jalal et al [274] 
used fructose fed rats as a model for insulin resistance and examined the effect of garlic 
extracts upon glucose handling as measured by glucose tolerance tests. This study suggests 
garlic extract could improve glucose handling in this rat model. However, this study used 
essentially laboratory prepared raw garlic extracts in high doses (500mg/kg) and administered 
them intravenously. The researchers used intraperitoneal glucose tolerance tests which have no 
human comparison. 
Lui et al [275] studied the effect of garlic oil or diallyl trisulphide (organosulphur derivative of 
garlic) in streptozocin-induced diabetic rats on insulin secretion and insulin resistance as 
measured by HOMA-IR. This study found increased insulin production and reduced insulin 
resistance in this model after treatment with high doses of garlic oil and diallyl trisulphide. As 
mentioned previously, streptozocin induced diabetes is more synonymous with type 1 than 
type 2 diabetes and may be an inappropriate model to study insulin resistance. 
Eidi et al [276] also used a streptozocin-induced rat diabetes model and administered a short 
term (72 hr) ethanol extraction of garlic. This study found a significant increase in plasma 
insulin levels after treatment with the garlic extract. Interestingly, this study also suggested 
that garlic extract was more effective at increasing insulin levels than glibenclamide, a 
 62 
 
commonly used sulphonylurea. The same criticisms can be levelled at this model and both 
garlic extract and glibenclamide were administered in large doses. 
 
1.5.8 Garlic and blood pressure 
There have been numerous clinical studies which have employed various preparations of 
garlic to treat hypertension. 
In brief, there has been a heterogenic effect; some have shown garlic to have successfully 
reduced blood pressure whilst others have shown no effect (Table 4). However, these studies 
have used 3 different preparations of garlic (only 1 used AGE) and for different durations of 
treatment of between 12 and 23 weeks and with different methodologies, thus forming 
conclusions on the results is problematic. A recent meta-analysis [277] incorporating 11 
randomised control trials concluded that garlic reduced systolic blood pressure by an average 
of 8.36 mmHg and diastolic blood pressure by an average of 7.27 mmHg in hypertensive 
individuals, although this was not seen in normotensive individuals and none of the trials 
included patients with diabetes, nor did they include individuals on vasoactive medication. 
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Table 4: Summary of studies investigating garlic‘s effect on blood pressure in non-diabetic 
subjects. NT = normotensive (<140/90), HT = hypertensive (>140/90), PC = Placebo 
controlled 
 
Author 
No of 
subjects 
Study 
Design 
Duration Subjects 
Type of 
Garlic 
Duration & 
Dose 
Mean BP 
Pre-
intervention 
Mean BP 
Post-
intervention 
Auer et al 
1990 [363] 
40 
Parallel 
PC 
12 wks HT 
Kwai 
garlic 
powder 
600mg/day 
 
171/102 152/89* 
Alder et al 
1997 
[371] 
50 
Parallel 
PC 
12 wks NT 
Kwai 
garlic 
powder 
900mg/day 
 
123/83 118/80* 
Vorberg & 
Schneider1990 
[364] 
40 
Parallel 
PC 
16 wks HT 
Kwai 
garlic 
powder 
900mg/day 
 
144/91 138/87* 
Keisewetter et 
al 1993 [363] 
64 
Parallel 
PC 
12 wks Unknown 
Kwai 
garlic 
powder 
800mg/day 
 
SBP not 
reported/84 
SBP not 
reported/81 
Jain et al 1993 
[366] 
42 
Parallel 
PC 
12 wks NT 
Kwai 
garlic 
powder 
900mg/day 
 
129/82 130/81 
Saradeth et al 
1994 [367] 
52 
Parallel 
PC 
15 wks NT 
Kwai 
garlic 
powder 
600mg/day 
 
125/80 127/82 
Simons et al 
1995 [368] 
56 
Crossover 
PC 
12 wks NT 
Kwai 
garlic 
powder 
900mg/day 
 
127/80 119/76 
Steiner et al 
1996 
[369] 
82 
Parallel 
PC 
23wks NT 
Aged 
Garlic 
Extract 
2400mg/day 
 
134/84 126/82 
Zhang et al 
2000 
[370] 
27 
Parallel 
PC 
16wks NT 
Distilled 
Garlic 
Oil 
12.3mg/day 
 
117/72 113/68* 
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1.5.9 Garlic and LDL Cholesterol 
Active reduction of circulating atherogenic LDL cholesterol in high-risk individuals also 
reduces cardiovascular mortality. In patients with type 2 diabetes, a typical lipid profile is 
characterised by increased LDL cholesterol, low HDL cholesterol and high triglyceride 
concentrations. 
In vitro studies have suggested AGE can inhibit cholesterol synthesis in hepatocytes, [278] 
including by inhibition of HMG-Co A reductase [279], a similar action to that of statins.  
Clinical studies have also shown garlic to lower total cholesterol and triglycerides 
concentrations, though not all studies have been consistent (Table 5). A meta-analysis 
concluded that garlic does have modest cholesterol-reducing properties (total cholesterol 
reduced by 9.9%, LDL by 11.4%) in hypercholesterolaemic subjects [280], though the 
significant trials were smaller trials and the meta-analysis excluded some of the negative, 
longer trials. Moreover, these studies also used a variety of garlic preparations and 
methodologies, making it difficult to reliably interpret. Currently there is scanty evidence that 
garlic can reduce circulating LDL cholesterol in patients already taking LDL cholesterol-
lowering medications; nor have the hypolipidaemic properties of garlic been studied in type 2 
diabetic subjects. 
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Table 5: Summary of studies investigating garlic‘s effect on lipids in non-diabetic hyperlipidaemic subjects 
A
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r 
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f 
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s 
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y
 D
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n
 
D
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o
n
 
D
ai
ly
 D
o
se
 
S
u
b
je
ct
s 
T
y
p
e 
o
f 
G
ar
li
c Total Chol 
Pre-
intervention 
(mmol/l) 
Total Chol 
Post-
intervention 
(mmol/l) 
LDL 
conc 
pre 
garlic 
(mmol/l) 
LDL 
conc 
post 
garli
c 
(mmol
/l) 
A
d
le
r 
et
 a
l 
1
9
9
7
 [
3
7
1
] 
50 
Parallel 
PC 
12 
wks 
900mg 
 
HL GP 6.54 5.79* 4.39 
3.77
* 
D
e 
S
an
to
s 
et
 a
l 
1
9
9
3
 
[3
7
2
] 
52 
Parallel 
PC 
26 
wks 
800mg 
 
HL GP 6.92 6.31* 4.75 
4.30
* 
 
Ja
in
 e
t 
al
 
1
9
9
3
 
[3
6
6
] 
42 
Parallel 
PC 
 
12 
wks 
900mg HL GP 6.8 6.4* 4.8 
4.4* 
 
M
ad
er
 e
t 
al
 
1
9
9
0
 [
3
7
3
] 
261 
Parallel 
PC 
 
16 
wks 
800mg HL GP 6.9 6.1* 
Not 
reported 
Not 
repor
ted 
S
im
o
n
s 
et
 
al
 1
9
9
5
 
[3
6
8
] 
30 
Crossover 
PC 
12 
wks 
900mg 
 
HL GP 
6.72 
 
6.54 4.76 4.64 
N
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l 
et
 a
l 
1
9
9
6
 
[3
7
4
] 
115 
Parallel 
PC 
26 
wks 
900mg 
 
HL GP 
6.96 
 
6.91 4.96 
4.94 
 
S
u
p
er
k
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et
 a
l 
2
0
0
0
 
[3
7
5
] 
50 
Parallel 
PC 
12 
wks 
900mg 
 
HL GP 6.3 6.2 4.3 4.2 
T
u
rn
er
 
et
 a
l 
2
0
0
4
 
[3
7
6
] 
75 
Parallel 
PC 
12 
wks 
920mg NL GP 4.9 5.2 3.3 3.3 
V
an
 
D
o
o
rn
 e
t 
al
 2
0
0
6
 
[2
7
3
] 
90 
Parallel 
PC 
12 
wks 
2100mg NL GP 5.47 5.59 3.37 3.37 
* Statistically significant (p>0.05), PC = Placebo controlled, HL – Hyperlipidaemic (TC>6),  NL – 
Normolipidaemic (TC<6) 
 66 
 
1.6 Aims & Hypothesis 
The antioxidant effects of AGE coupled with the hypolipidaemic, anti platelet and 
antihypertensive properties would suggest that it has the potential to ameliorate oxidative 
stress, vascular inflammation and subsequently endothelial dysfunction. This triad of 
interlinked biochemical processes may underlie the complications of type 2 diabetes, 
particularly atherosclerosis. This Common Soil hypothesis may also be responsible for insulin 
resistance; key to the pathogenesis of type 2 diabetes itself.  
To date much of the evidence to support garlic as a potential anti-diabetic agent has been in in-
vitro and animal studies. There have been no clinical studies looking at the effect of garlic 
upon these novel cardiovascular markers in subjects with type 2 diabetes. Therefore, this study 
aims to test the hypotheses that; 
 AGE improves markers of oxidative stress, endothelial function and insulin resistance 
in subjects with type 2 diabetes. 
 AGE improves markers of  inflammation in these same subjects 
 AGE improves traditional risk factors for cardiovascular disease such as LDL-
cholesterol and blood pressure. 
If these hypotheses are proven it would support further large scale clinical studies to ascertain 
whether AGE could have a role in ameliorating cardiovascular disease in people with type 2 
diabetes.  
The secondary aim is to examine the relationship between insulin resistance, oxidative stress, 
endothelial function and vascular inflammation. Our hypothesis states that these processes are 
interdependent. (See figure 3) 
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Chapter 2: Methods 
A randomised, double blind, placebo controlled study in 26 type 2 diabetic patients was 
undertaken to investigate the effect of AGE upon endothelial function, oxidative stress, 
vascular inflammation and a selection of metabolic parameters. 
2.1 Subjects 
26 type 2 diabetes subjects who were deemed to be at high cardiovascular risk (30% risk of a 
cardiovascular event within the next 10 years [281] were recruited. These subjects were 
identified using the Diabeta 3 electronic database of outpatients of the Diabetes Centre of 
Portsmouth Hospitals NHS Trust and those who had previously undertaken trials in the 
department. All subjects gave written informed consent. The Hampshire and Isle of Wight 
Research Ethics Committee gave their approval for this study (REC Ref No: 05/Q1704/79). 
The inclusion criteria included type 2 diabetes patients aged between 18-70 years, who were 
not treated with insulin. Exclusion criteria included established cardio or cerebrovascular 
disease, treatment with insulin or Warfarin. 
The presence of vascular disease was determined by obtaining a history from the patients and 
clinical examination. The Rose questionnaire was used at the first visit. The Rose 
questionnaire was developed and adopted by the WHO in 1962 [282]. It has been used 
extensively since and validated against clinical findings and thallium scans for detecting occult 
ischaemic heart disease [283, 284]. It was used in our exclusively white European population. 
A 12 lead ECG was also performed to investigate occult coronary artery disease. 
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2.2 Clinical Protocol 
Once recruited, each subject underwent a direct clinical history and examination. Body weight 
was measured (without shoes) using an electronic balance (Welch Allyn, 52000 Series). 
Baseline blood pressure was measured by an automated Sphygmomanometer with the subject 
having been supine in quiet surroundings for at least 5 minutes.  
All participants arrived in the Diabetes Department, Queen Alexandra Hospital by 9am in the 
morning after fasting overnight. A catheter was inserted into a superficial vein and 3 samples 
of 10 ml of blood were taken 5 minutes apart. Baseline fasting investigations included 
measurements of plasma lipids (total cholesterol, high density lipoprotein cholesterol and 
triglyceride) serum urea and serum electrolytes, liver function tests, INR. Glycaemic control 
was measured using HbA1c and fructosamine. Measurements were also made of insulin 
resistance, endothelial function, vascular inflammation and oxidative stress as described 
below.   
Once baseline assessments had been concluded, the subjects were given either a commercial 
garlic preparation (Aged Garlic Extract; ―Kyolic‖ Wakunaga Pharmaceuticals, Mission Viejo, 
CA, USA) or a placebo. Double blind, randomised allocation (randomization and blinding 
performed in hospital pharmacy) of the placebo or garlic treatment was undertaken. Subjects 
took 4 capsules per day (1200mg) for 4 weeks. There was then a 4 week washout period and 
then the subjects entered the crossover arm (see Figure 8). 
The dose and duration of treatment was chosen based upon previous studies using AGE [242, 
261]. Compliance levels were monitored with a tablet count at the end of each 4 week 
treatment period. 
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Figure 8. Diagram of Clinical Protocol 
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2.3 Metabolic markers 
Metabolic markers including fasting glucose, insulin (measured by Radio-immuno Assay), 
HOMA-IR, fructosamine, lipid profile (total cholesterol, HDL-cholesterol and triglycerides) 
(colorimetric assay), liver function tests, urea and electrolytes were also measured at each 
visit. HbA1c was only measured at baseline visit since the study period was too short to detect 
any AGE-induced change in this measurement. HbA1c was measured by HPLC (Menarini 
Diagnostics, Wokingham, UK; intra-assay coefficient of variation (CV 1.5%). Plasma total 
cholesterol concentration was measured by esterase and oxidase conversion (Advia 1650, 
Bayer Diagnostics, Newbury, UK; CV<1.9%) and HDL-cholesterol and plasma triglyceride 
concentration by enzymatic determination (Advia 1650, Bayer Diagnostics, NEWBURY, UK; 
CV<1.7%) 
2.4 Homeostasis Model Assessment 
Calculation of the insulin sensitivity index or insulin resistance was carried out using the 
HOMA (Homeostasis Model Assessment) method. [285] 
HOMA uses a mathematical model to estimate steady state beta cell function (%B) and insulin 
sensitivity (%S), as percentages of a normal reference population. These measures are based 
upon non-steady state estimates of beta cell function and insulin sensitivity derived from 
clinical stimulatory models such as the hyperinsulinaemic clamp, the hyperglycaemic clamp 
and the oral glucose tolerance test. 
In 1976, Robert Turner and Rury Holman developed the concept that fasting plasma insulin 
and glucose concentrations were determined, in part, by a hepatic-beta cell feedback loop. 
They postulated that elevated fasting glucose levels reflected a compensatory mechanism that 
maintained fasting insulin concentrations when there was a reduced insulin secretory capacity, 
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and that fasting insulin concentrations were elevated in direct proportion to diminished insulin 
sensitivity. A mathematical feedback model based on these hypotheses was constructed to 
estimate the degrees of beta cell function and insulin sensitivity that would equate to the 
steady state plasma glucose and insulin levels observed in an individual. 
In 1985, David Matthews et al published an expanded and more comprehensive structural 
model known as the Homeostasis Assessment Model (HOMA). This model took greater 
account of peripheral glucose uptake and could use fasting levels of insulin [285]. These gave 
approximate values of steady state beta cell function (%B) and introduced HOMA IR (insulin 
resistance) which is the reciprocal of %S (100/%S).  
 Jonathan Levy et al published an updated HOMA model (HOMA2) in 1998 which took 
account of variations in hepatic and peripheral glucose resistance, increases in the insulin 
secretion curve for plasma glucose concentrations above 10 mmol/L  and the contribution of 
circulating proinsulin, which has a small biological action and secretion is increased in  type 2 
diabetes [286]. The model was recalibrated also to give %B and %S control values of 100% in 
normal young adults when using more modern assays for insulin. 
In 2004, the HOMA Calculator was released. This provides quick and easy access to the 
HOMA2 model in the form of computer software. This is the model that was used in this 
project to derive estimates of insulin resistance in our subjects. 
Plasma insulin and fasting plasma glucose were collected at the beginning of each visit of each 
of the subjects. These were repeated at 5 minute intervals to give a total of 3 pairs of results 
and the average of these was used to calculate insulin resistance. An example of the software 
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used is shown below. 
 
Figure 9: Screenshot of the HOMA IR calculator 
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2.5 Oxidative Stress Markers 
Markers of oxidative stress and antioxidant defence included whole blood ratio of reduced and 
oxidized glutathione [GSH/GSSG] (enzymatic colourimetric assay), plasma total antioxidant 
status [TAOS] (enzymatic colorimetric assay) and plasma lipid hydroperoxides [LHP] 
(enzymatic colorimetric assay).  
2.5.1 GSH/GSSG (Glutathione Ratio) 
Background 
Glutathione (GSH) is the principal thiol intracellular antioxidant and as such the relative 
amount of intracellular reduced and oxidised GSH is a measure of the cellular redox status. 
Thornalley et al, 1996 [77] and Jain et al 1994 [78] showed a negative correlation between 
reduced erythrocyte glutathione and diabetic complications suggesting antioxidant defences 
were depleted by chronic oxidative stress of type 2 diabetes. These studies also showed a 
negative correlation between the duration of diabetes and the levels of reduced glutathione. 
Thornalley postulated that an inherent low level of reduced glutathione in an individual may 
predispose them to diabetic complications, a phenomenon that is noted clinically. In diabetic 
patients, a significant increase in plasma free radical concentrations can contribute to a 
reduction in plasma GSH concentration and to declining blood GSH/GSSG ratios and this can 
effect insulin action [287].  
Using euglycaemic clamp studies, Paolisso also found that supplementation of GSH lead to an 
improvement of whole body glucose disposal [287]. 
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Technique 
2 ml of blood was collected from patients in an EDTA (Ethylenediamine tetraacetic acid) 
bottle. This was then put into a plain bottle to which 1 ml 0.5mM EDTA/10% (w/v) SSA 
(Sulpho-salicylic acid) was added. This was further centrifuged at 2580x g (IEC centra- 3C, 
International Equipment Company, Milford, USA) for 5 minutes. The supernatant was then 
stored in the –85° C freezer in the Oncology Laboratory at Queen Alexandra Hospital, 
Portsmouth. 
Glutathione ratio was assessed using the GSSG reductase/5,5‘-dithio-bis(2-nitrobenzoic acid) 
re-circulating method following derivatisation of GSSG with 2-vinylpyridine [288, 289].  
GSH was assessed photometrically in a plate reader at 37° C in a GSH reductase / 5,5‘-dithio-
bis(2-nitrobenzoic acid) (DTNB) recirculating assay essentially as described by Tietze (Tietze, 
1969). The 100 µl assay well comprised of (final concentration): 70µl DTNB (0.6 mM); 10µl 
-NADPH (0.5 mM); 10µl sample; 10µl GSH reductase (2.5 U/ml). Reagents were dissolved 
in sodium phosphate buffer (120mM, pH 7.4) +6.3mM EDTA. The recirculating assay was 
initiated after 10 minute incubation at 37° C by the addition of GSH reductase and the initial 
rate determined from the absorbance increase measured every 10 seconds at 405nm over 1 
minute. For the selective measurement of GSSG (=2GSH), thiols were first derivatised (1 
hour) with 2-vinylpyridine (2-VP) in the presence of triethanolamine (TEA) (2µl 2-VP and 6 
µl TEA added to the 100µl sample). This procedure was sufficient to fully derivatise up to at 
least 15mM GSH. 
The intra-assay %CV is <3, while the inter-assay CV is <10. 
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2.5.2 Plasma Lipid Hydroperoxides (LHP) 
Background 
Lipid hydroperoxides are formed when lipids are exposed to free radical activity and as such 
plasma levels have been used as a marker of oxidative stress. Both Nourooz-Zadeh et al [74] 
and Martin-Gallan et al [75] showed that LHP‘s are raised in those with diabetes, whether or 
not they have complications. Sugherini et al 2005 [290] found that there is a correlation 
between levels of plasma LHP and HbA1c. They combined LHP with a measure of total 
antioxidant status to give a ―Redox Compensation Index‖ which was negatively correlated 
with glycosylated haemoglobin. The technique used was first described by Ruiz et al in 1997 
[314]. 
 
Technique: 
2 ml of blood collected from the patient was put in a heparinised tube. This was centrifuged at 
2580 x g (IEC centra- 3C, International Equipment Company, Milford, USA) for 5 minutes. 
Supernatant plasma was extracted and then stored in the -85° C freezer.  
700µl of buffer (124mmol/l Tris HCl/0.2mmol/l EDTA) was placed in a 1 ml microcuvette 
and the 200 µl of the sample added. This was then incubated for 5 minutes at room 
temperature. 50µl of 0.2mmol/l of NADPH, 10µl of glutathione peroxidase (16kU/l) and 
100µl of reduced glutathione (4.25mmol/l) were then added. This was then incubated at 37°C 
for 5 minutes. The spectrophotometric absorbance at 340nm was measured. A further 10 
minutes of incubation at 33°C was carried out after the addition of 10µl of butylated 
hydroxytoluene solution (20g/l) to stop lipid peroxidation. The spectrophotometric absorbance 
at 340nm was measured for a second time. The difference between the 2 absorption 
 76 
 
measurements is proportional to the sample hydroperoxide content. These values were 
obtained from comparison with the standard curve. The standard curve was obtained by 
performing the process described above with standard dilutions (25 to 300µmol/l) of t-butyl 
hydroperoxide prepared from an aqueous solution of the pre-prepared 60mmol/l stock 
solution. 
2.5.3 Plasma Total Antioxidant Status (TAOS) 
Background 
In 1999, a photometric microassay was developed by Laight et al [291] for the assessment of 
plasma total antioxidant status in plasma at physiological pH and temperature. Plasma TAOS, 
expressed as the ascorbate equivalent antioxidant concentration, was found to be significantly 
reduced in animal models treated with oxidant compounds for 7 days and thus inversely 
related to oxidant stress. It has since been used successfully in many clinical trials, including 
those with diabetes [292, 293, 294]. 
Technique 
Two ml of blood was collected from the patient in an EDTA bottle. This was then centrifuged 
at 2580 x g (IEC centra- 3C, International Equipment Company, Milford, USA) for 5 minutes. 
The supernatant plasma was stored in a –85° C freezer. 
TAOS was assessed by the ability of plasma to inhibit the peroxidase-mediated accumulation 
of ABTS
+
 radical [2,2‘-azino-bis (3-ethylbenzthiazoline-6-sulfonic acid)] [291].  
The generation and detection of ABTS
+ 
was a modification of the spectrophotometric method 
described by Arnao et al [295] in the assessment of the total antioxidant status of food, 
adapted to become suitable for use with plasma by employing an inhibition assay with a fixed 
time point [296]. 
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The reaction mixture consisted of 20µl ABTS (2mM), 10µl horseradish peroxidase 
(30mU/ml), 20µl H2O2 (0.1mM) and 50µl phosphate-buffered saline (pH 7.4), to make a total 
volume of 100µl in a 96-well plate. The reaction was initiated by the addition of H2O2 and 
conducted at 37° C. The increase in absorbance at 405 nm, reflecting the accumulation of 
ABTS
+, was determined in a Molecular Devices ―Versamax‖ microplate reader. All 
determinations were made at least in duplicate. 
 For TAOS, the intra-assay %CV is <3, while the inter-assay CV is <10 
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2.6 Biochemical Markers of Inflammation 
The marker used for endothelial inflammation was highly sensitive C-reactive protein 
(HsCRP) (Elisa). 
2.6.1 Highly sensitive C-reactive protein (hsCRP) 
Cardiophase hsCRP is a suspension of polystyrene particles coated with mouse monoclonal 
antibodies to hsCRP. These are diluted with the plasma sample (ratio 1:20) and allowed reach 
room temperature. The particles get aggregated when mixed with samples covered with CRP. 
When light is then passed through the sample it is scattered by the aggregates. The intensity of 
the scattered light is proportional to the concentration of the relevant protein in the sample. 
The mixture of hsCRP and the sample were measured on the DADA BEHRING BN prospec 
system analyzer. The result was then analysed by comparison with a standard of known 
concentration. The assigned values of CRP were standardized against the international 
reference preparation BCR-CRM 470 [313]. The results from the analyzer were evaluated 
automatically and represented in mg/L. This work was undertaken in the biochemistry 
laboratory at St Thomas‘s Hospital, London. 
2.7 Measurement of Endothelial Function 
2.7.1 Digital Plethysmography 
Background 
It has been established that the Aortic Pulse Wave Velocity (PWV) is a marker of arterial 
stiffness and arterial ageing. Increased stiffness in the aorta and the large arteries transmits 
pulse pressure waves from the left ventricle more rapidly. This is a phenomenon found in 
ageing of the arteries and may be accelerated in hypertensive and diabetic individuals. Aortic 
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PWV is an independent predictor of cardiovascular mortality in a diabetic population, and may 
be more sensitive than systolic BP [297].  
Dawber et al [298] established the link between the loss of the dicrotic notch in the digital 
volume pulse (DVP) and coronary artery disease whilst investigating the Framington Study 
Group. He postulated that the dicrotic notch was not due to the closure of the aortic valve as 
previously thought but represented the elasticity of the arterial tree. Digital volume pulse has a 
distinctive contour which Dawber divided into 4 classes (Fig. 8)  
Table 6: Dawber‘s classification of digital volume pulse 
 
 
 
 
CLASS  CHARACTERISTIC 
1  A distinct notch is seen on the downward slope of the pulse wave 
2  No notch develops, but line of descent becomes horizontal 
3  No notch, but there is well-defined change to the angle of descent 
4  No notch develops or no change occurs in angle of decent 
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Figure 10. Diagrams of the typical digital pulse waveforms obtained (adapted from Dawber 
[298])
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Class 1 was more common in young fit individuals whilst class 4 was more prevalent in those 
in older age groups or those with coronary artery disease. Class 4 was also more common in 
those with diabetes or hypertension. 
The DVP contour has since been shown to reflect pressure wave changes seen in both the 
aorta and the carotid arteries [299, 300].  This suggests that the first peak is a component of 
the pressure created by contraction of the left ventricle. The distinctive second wave produced 
in the peripheral pulse represents a reflected, backward wave from the arterial tree of the trunk 
and limbs [301] and the relative velocity of this peak can be used as a surrogate for the 
elasticity of the resistance vessels [302]. The time between these first and second peaks in the 
digital volume pulse has been also been used as a surrogate marker of Aortic PWV [303].  
The reflective index (RI) is defined as the ratio of the amplitude of the reflected wave to the 
first peak, expressed as a percentage. 
 
Figure 11. Calculation of Reflective Index (adapted from Micromedical Ltd) 
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This reflection index has been used to study the effects of vasoactive medications and has 
been shown to closely reflect pressure changes seen in the radial and aortic pulses. 
Chowiencyzk et al has also validated the use of the reflective index in diabetic and non 
diabetic populations [304]. 
DVP can be measured using photoplethysmography, which is transmission of infra-red light 
through the finger. The absorption of light is proportional to the volume of blood in the 
capillaries and thus is proportional to the digital pulse wave. 
Endothelial independent vasodilators have been used to assess the effect of an intervention 
independent of any endothelial involvement. The most commonly used agent has been 
glyceryl trinitrate (GTN). GTN is a nitric oxide donor and acts independently of endothelial 
function. Endothelial dependent agents, such as salbutamol, stimulate the release of nitric 
oxide from the endothelium [305]. If these agents are used alongside each other, an effect of 
an intervention could be described as either endothelial dependent or independent. The RI has 
been shown to be sensitive to the use of both GTN and beta adrenergic agonists and therefore 
these could be used as a measurement of the vasodilator component of endothelial function. 
[306].  
Technique 
Measurements were made to determine the digital volume waveform [DVW] using the 
photoplethysmography apparatus (Micro Medical Pulse Trace, Rochester, Kent, UK). This 
technique was previously described by Chowienczyk 1999 [304]. 
Each subject had the probe attached to an index finger for 20 minutes, resting supine, before 
measurements were taken. Digital pulse wave readings were taken at baseline and the software 
calculated reflective index (RI). This was then repeated following administration of a 
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sublingual glyceryl trinitrate (GTN). GTN is an endothelium-independent vasodilator and thus 
acted as a control. These readings were then repeated following inhaled salbutamol (an 
endothelium dependent vasodilator). Three readings were taken at baseline and an average 
taken. 500mcg of sublingual GTN was then administered in tablet for. Readings were taken at 
3 and 5 minutes. A washout period of 20 minutes was allowed after which another reading 
was taken to confirm the return to baseline. Inhaled Salbutamol (400 mcg) was administered 
using a standardised technique via a spacer device, and readings taken at 10, 12 and 15 
minutes. An average of the readings was taken.  
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2.7.2 Urine Albumin Creatinine Ratio (ACR)  
An early morning urine sample was taken at each visit. This was analysed in the biochemistry 
laboratory at Queen Alexandra Hospital, Portsmouth. There is a well established association 
between vasoactive endothelial dysfunction in those with diabetes and microalbuminuria [307-
312]. 
Urine albumin was measured by radioimmunoassay (CV < 9%) and urine creatinine 
concentration by an end-point Jaffe reaction (CV <6%).  
2.8 Statistical analysis  
Statistical software Graphpad Instat 3 and XLStat 2007 were used for statistical analysis.  
 The Kolmogorov-Smirnov test (KS test) was used to assess whether distributions were 
parametric or non-parametric.   
 Repeated measures of ANOVA (Analysis of Variance) were used to compare 4 sets of 
values obtained. These were: value at baseline; value after AGE intervention; value at 
baseline (after washout period) and value after placebo. All combinations were 
examined but only post intervention values were clinically relevant.  
 For parametric values, post-tests were undertaken using the Bonferroni method.  
 Friedmans test with Dunn‘s post-test were used if the distribution was non-parametric.  
For the purpose of this study, normally distributed data has been expressed as mean ± 1 
standard deviation (SD) while the non-parametrically distributed data are shown as median ± 
interquartile ranges 
Spearman rank correlation test was used to determine the associations between baseline 
measurements in each of the variables measured. A p value <0.05 was considered to be 
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significant. Multiple linear regression analysis was performed to account for confounding 
factors in any associations found. 
Missing values were small in number (<5%) and where possible were repeated. The remaining 
missing values occurred randomly and were excluded from the analysis (casewise deletion). 
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Chapter 3: Results 
3.1 Subjects 
30 subjects were recruited and met the inclusion and exclusion criteria. 2 discontinued the 
study due to side effects of AGE (indigestion) and 2 due to other health reasons. Twenty six 
subjects successfully completed the study. Intention to treat analysis was not undertaken. 
3.2 Baseline Characteristics (see Table 7) 
The mean age of the participants was 61 ± 8 years and the mean duration of diabetes was 6±3 
years. 17 were male and 9 female. 7 were current smokers. The mean BMI (body mass index) 
was 32.2±5.1 kg/m
2
, meaning the majority of subjects were obese (BMI 30-35). 9 out of 26 
subjects were taking an ACE inhibitor throughout the study, 25/26 were taking a statin, 16/26 
were taking 75mg aspirin and 19/26 were taking metformin (see figure 12). 
The baseline characteristics of the cohort were typical of patients found in local GP and 
diabetes outpatient clinics. 7 (26%) were current smokers and this percentage is in keeping 
with local smoking rates. Analysis of the BMI of the subjects showed that 24/26 (92%) of 
subjects were at least overweight (BMI>25). Of these 24 subjects, 33% were overweight (BMI 
25-30 kg/m
2
), 58% obese (BMI 30-40 kg/m
2
) and 9% extremely obese (BMI >40 kg/m
2
). 
Given that a high percentage of our cohort were taking statins, metformin, aspirin and/or anti 
hypertensive medications, baseline metabolic parameters were generally well controlled (see 
section 3.2.1) 
None of the subjects were taking additional garlic supplements. Garlic in usual diet was not 
measured. 
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Table 7: Baseline Characteristics of Subjects 
 
 
Subject no Age (yrs) 
Diabetes 
Duration 
(yrs) 
Sex Height (m) Weight(Kg) BMI(Kg/m2) Smokers Statins Metformin 
8001 51 
2 M 
186.5 125.8 
36.2 YES YES YES 
8002 64 
6 M 
174 90.4 
29.9 NO YES NO 
8003 70 
18 M 
186 85.2 
24.6 EX TES YES 
8004 57 
6 F 
171 106.8 
36.5 YES YES YES 
8005 60 
5 M 
185 92 
26.9 NO YES NO 
8006 58 
9 M 
177.5 110.7 
35.1 YES YES YES 
8007 54 
7 M 
178 109.2 
34.1 NO YES YES 
8009 60 
6 F 
163 94.3 
35.4 YES YES YES 
8010 71 
8 M 
176.5 91.2 
29.3 NO YES YES 
8011 65 
11 F 
152 68.6 
29.7 NO YES YES 
8013 61 
5 M 
178 102.7 
32.5 NO YES NO 
8014 62 
9 M 
183.5 114.5 
33.9 NO YES YES 
8015 66 
8 F 
167.5 94.9 
34 NO YES NO 
8016 54 
6 F 
164.5 63.4 
23.4 YES NO NO 
8017 69 
11 F 
170.5 83.1 
28.6 NO YES YES 
8019 59 
2 M 
168.5 73.6 
26.1 NO YES NO 
8023 40 
6 F 
176 107.5 
34.7 NO YES YES 
8024 64 
1 M 
164.5 89.6 
33.3 NO YES YES 
8025 70 
5 M 
178 106.5 
33.6 NO YES YES 
8026 70 
6 F 
180 97.9 
30.2 NO YES YES 
8027 63 
4 M 
171 91.4 
31.3 EX YES NO 
8028 59 
3 M 
187 93.9 
26.9 YES YES YES 
8029 49 
5 M 
171 130.5 
44.6 NO YES YES 
8030 52 
2 M 
192 117.5 
31.9 EX YES YES 
8031 70 
2 M 
179 142.2 
44.4 YES YES YES 
8032 75 
5 F 
167 83.5 
29.8 NO YES YES 
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Figure 12. Percentage of subjects on vasoactive medication (HTN = anti-hypertensive 
medication) 
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Figure 13. Percentage of active smokers amongst group 
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Table 8: Baseline Metabolic parameters of subjects 
Subject 
no 
HbA1c 
(%) 
Total Cholesterol 
(mmol/L) 
HDL 
(mmol/L) 
Triglycerides 
(mmol/L) 
Systolic 
BP(mmHg) 
Diastolic BP 
(mmHg) 
8001 
6.7 4.25 0.84 1.36 146 92 
8002 
7 2.9 0.83 1.11 103 66 
8003 
6.4 4.53 1.33 0.66 136 75 
8004 
8.1 6.04 0.92 2.02 138 83 
8005 
5.5 5.42 1.91 1.45 151 86 
8006 
6.1 4.67 1.06 1.8 131 73 
8007 
8.6 4.09 0.9 2.23 122 77 
8009 
7.5 3.74 1.06 1.52 129 77 
8010 
6.6 3.16 0.87 1.18 126 63 
8011 
6.7 3.85 1 1.61 131 78 
8013 
5.6 4.05 1.23 1.32 118 73 
8014 
6.7 3.25 1.05 1.7 128 74 
8015 
6.6 4.37 1.3 1.27 112 69 
8016 
6.9 4.8 1.46 1.22 99 58 
8017 
6.4 3.89 1.21 1.13 144 66 
8019 
6 4.68 1.47 1.62 141 78 
8023 
8.4 5.69 0.94 8.24 149 91 
8024 
6.8 4.43 0.88 3.52 165 99 
8025 
7.2 3.72 0.69 3.88 144 74 
8026 
9.7 3.71 0.79 1.57 133 77 
8027 
5.9 4.29 0.98 1.44 124 70 
8028 
7.4 3.48 0.63 3.48 116 76 
8029 
9.5 3.89 0.87 2.73 132 78 
8030 
8.1 4.04 0.99 2.56 105 58 
8031 
8.8 3.54 0.68 1.1 120 67 
8032 
7.4 5.84 1.06 3.23 144 68 
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3.2.1 Baseline Metabolic Markers 
The baseline metabolic markers of our group (see table 8) were close to the NICE 
recommendations for this patient group [315]. The glycaemic control amongst the subjects at 
baseline was near optimal with a mean HbA1c of 7.2±1.13% (NICE target<7.5%). Mean 
plasma total cholesterol concentration at baseline was 4.24±0.81mmol/l (Dept of Health target 
<5mmol/l). Mean HDL cholesterol concentration was 1.04±0.29mmol/l (NICE Target 
>1mmol/l) and mean plasma triglyceride concentration was 2.11±1.51mmol/l (NICE 
target<2mmol/l). Mean blood pressure at baseline was 130/75 ±16/10mmHg (NICE target 
140/80mmHg). 
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Table 9: Baseline comparisons before and after washout period 
Parameter Baseline Pre-placebo Baseline pre AGE P value 
Plasma total 
Cholesterol (mmol/l) 
4.2±0.8 4.2±0.9 0.83 
Plasma HDL 
Cholesterol (mmol/l) 
1.0±0.3 1.0±0.3 0.24 
Plasma triglycerides 
(mmol/l) 
1.6 IQR 1.2 1.4 IQR 0.7 0.01
w 
Fructosamine 
(µmol/l) 
284±46 274±33 0.48 
Diastolic BP(mmHg) 74.8±9.8 74.7±7.5 0.92 
Systolic BP(mmHg) 130.3±15.9 130.3±14.0 0.98 
RI Change post 
Salbutamol 
8.0 IQR 4.7 6.5 IQR 9.7 0.45
w 
Insulin resistance 
(HOMA-IR) 
2.5±2.0 1.9 ±1.1 0.13 
LHP(µM) 158.3±97.0 144.7±55.4 0.89
w 
GSH/GSSG 17.0 IQR 15.1 18.8 IQR 21.8 0.43
w 
Total 
Glutathione(µM) 
698.0 ±193.7 690.2 ±177.9 0.81 
TAOS (µM) 62.9 ±3.6 63.1±3.2 0.76 
HsCRP (mg/l) 1.8 IQR 2.1 2.1 IQR 18.3 0.49
w 
w
= Wilcoxon (non parametric) 
There were no significant differences in the baselines prior to each of the treatment arm apart 
from triglycerides (Table 9). This would suggest the washout period was effective. The 
difference between the triglyceride baselines would not be clinically significant.
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3.3 Effect of AGE and placebo upon measured outcomes 
Metabolic markers 
3.3.1 Weight Change 
The mean change in weight following treatment with AGE was 0.5±1.1kg. 27% lost weight. 
After treatment with placebo the weight change was 0.1±1.3kg. 46% lost weight. This result 
was tested using a Student two tailed t-test and found not to be statistically significant 
(p=0.24). The data for the subjects is shown in table 10. 
Table 10: Weight change after 4 weeks treatment (kg) 
Subject no Post Placebo Post AGE 
8001 0.7 0.9 
8002 0.7 0.6 
8003 -1.2 0.8 
8004 -0.8 -1.6 
8005 1 -0.5 
8006 2.5 0 
8007 0.6 1.4 
8009 -0.4 1.7 
8010 0.9 0.8 
8011 0.4 0.3 
8013 -0.1 1.6 
8014 -2.6 0.4 
8015 -1.3 0.4 
8016 -1.8 1.2 
8017 1.2 1.7 
8019 0.3 -0.1 
8023 -0.1 2.3 
8024 0.8 -1 
8025 1 0.6 
8026 -1.3 -1.9 
8027 1.8 1.2 
8028 1.3 0.3 
8029 -2.8 2.4 
8030 1.9 -0.3 
8031 -0.7 -0.5 
8032 -0.3 0 
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3.3.2 Systolic Blood Pressure 
Baseline mean systolic blood pressure (BP) in the treatment arm was 130.3±14.0mmHg. 
Following treatment with AGE it was 130.8±14.6mmHg.  
In the placebo arm, baseline mean systolic BP was 130.3±15.9mmHg (n=26). Following 
treatment with placebo it was 131.6±17.5mmHg. 
 The data was distributed parametrically. Repeated measures ANOVA testing showed no 
statistically significant difference in either arm (p=0.94). 
The data for the subjects is shown in table 11. 
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Table 11: Changes in Systolic BP (mmHg) 
Subject no Baseline Pre-Placebo Post Placebo Baseline pre-AGE Post AGE 
8001 146 137 125 134 
8002 103 108 105 120 
8003 136 140 138 143 
8004 138 122 131 120 
8005 151 138 149 164 
8006 131 141 129 130 
8007 122 120 130 116 
8009 129 127 122 129 
8010 126 148 131 147 
8011 131 132 128 137 
8013 118 114 127 127 
8014 128 122 124 121 
8015 112 111 104 120 
8016 99 111 119 105 
8017 144 140 117 120 
8019 141 121 136 126 
8023 149 145 132 148 
8024 165 169 148 163 
8025 144 164 146 118 
8026 133 122 129 119 
8027 124 132 147 134 
8028 116 116 113 119 
8029 132 125 132 130 
8030 105 110 115 128 
8031 120 137 152 131 
8032 144 169 159 153 
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3.3.3 Diastolic blood pressure 
In the treatment arm, baseline mean diastolic BP was 74.7±7.5mmHg. Following treatment 
with AGE it was 73.9±7.7mmHg. In the placebo arm, baseline mean diastolic BP was 
74.8±9.8mmHg. After treatment with placebo it was 75.1±8.3mmHg.  
KS test showed the data to be distributed parametrically. Repeated measures ANOVA testing 
showed no statistically significant difference in either arm (p=0.81). The data for the subjects 
is shown in table 12. 
Table 12: Changes in Diastolic BP (mmHg) 
Subject no Baseline Pre-Placebo Post Placebo Baseline Pre-AGE Post AGE 
8001 92 84 74 84 
8002 66 70 68 77 
8003 75 79 70 75 
8004 83 68 76 73 
8005 86 76 83 80 
8006 73 85 77 78 
8007 77 77 79 75 
8009 77 80 79 79 
8010 63 66 65 64 
8011 78 77 76 77 
8013 73 64 77 73 
8014 74 76 77 80 
8015 69 68 62 65 
8016 58 62 66 52 
8017 66 60 63 64 
8019 78 70 66 71 
8023 91 85 85 88 
8024 99 97 86 85 
8025 74 82 74 70 
8026 77 74 75 80 
8027 70 74 74 75 
8028 76 76 77 73 
8029 78 77 88 74 
8030 58 67 65 64 
8031 67 80 87 72 
8032 68 79 73 74 
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3.3.4 Plasma Total Cholesterol 
In the treatment arm, the baseline mean total plasma cholesterol was 4.22±0.92mmol/l. 
Following treatment with AGE the mean total plasma cholesterol was 4.22±0.79mmol/l. 
In the placebo arm, the baseline mean total plasma cholesterol was 4.24±0.81mmol/l. 
Following treatment with placebo the mean total plasma cholesterol was 4.18±0.95mmol/l. 
KS testing showed the data to be distributed parametrically. Repeated measures ANOVA 
testing showed no statistically significant difference in either arm (p=0.96) 
The data for the subjects is shown in table 13. 
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Table13: Changes in Plasma Total Cholesterol (mmol/l) 
Subject no Baseline  Pre-Placebo Post placebo Baseline Pre-AGE Post AGE 
8001 4.25 3.99 4.00 4.46 
8002 2.90 3.26 2.69 3.29 
8003 4.53 4.76 5.5 4.34 
8004 6.04 5.71 5.65 5.32 
8005 5.42 4.87 4.85 4.68 
8006 4.67 4.04 3.98 4.00 
8007 4.09 3.92 4.05 3.82 
8009 3.74 3.63 5.09 3.51 
8010 3.16 3.10 3.02 2.93 
8011 3.85 3.68 4.39 4.76 
8013 4.05 3.50 3.75 3.93 
8014 3.25 3.28 3.01 3.47 
8015 4.37 3.72 5.13 4.71 
8016 4.80 4.60 5.09 5.44 
8017 3.89 3.97 3.70 5.88 
8019 4.68 5.48 4.70 5.07 
8023 5.69 6.61 4.82 4.41 
8024 4.43 4.33 4.14 4.11 
8025 3.72 3.55 3.7 3.72 
8026 3.71 3.43 3.5 3.67 
8027 4.29 4.62 4.87 4.89 
8028 3.48 3.06 2.55 2.94 
8029 3.89 3.42 3.62 3.38 
8030 4.04 3.86 3.68 4.16 
8031 3.54 4.10 4.06 3.60 
8032 5.84 6.27 6.17 5.36 
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3.3.5 Plasma HDL Cholesterol 
In the treatment arm the baseline mean plasma HDL cholesterol was 1.01±0.28mmol/l. After 
treatment with AGE it was 1.01±0.27mmol/l. 
In the placebo arm, the baseline mean plasma HDL cholesterol was 1.04±0.29mmol/l. 
Following treatment with placebo, the mean plasma HDL cholesterol was 1.00±0.28mmol/l. 
KS showed the data to be distributed in a parametric fashion. Repeated measures ANOVA 
testing showed no statistically significant difference in either arm (p=0.46). 
 The data for the subjects is shown in table 14. 
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Table 14: Changes in HDL Cholesterol (mmol/l) 
Subject no Baseline Pre-placebo Post placebo Baseline Pre-AGE Post AGE 
8001 0.84 0.81 0.77 0.84 
8002 0.83 0.76 0.83 0.82 
8003 1.33 1.35 1.57 1.40 
8004 0.92 0.90 0.93 0.90 
8005 1.91 1.79 1.64 1.54 
8006 1.06 0.95 0.86 0.88 
8007 0.9 0.82 0.89 0.85 
8009 1.06 1.27 1.32  
8010 0.87 0.83 0.93 0.89 
8011 1.00 1.01 0.96 0.98 
8013 1.23 1.00 1.22  
8014 1.05 1.13 0.98 1.00 
8015 1.30 1.01 1.16  
8016 1.46 1.28 1.44 1.59 
8017 1.21 1.33 1.23 1.29 
8019 1.47 1.47 1.31 1.46 
8023 0.94 1.13 0.99 0.91 
8024 0.88 0.79 0.77 0.89 
8025 0.69 0.68 0.63 0.71 
8026 0.79 0.66 0.81 0.73 
8027 0.98 1.01 1.14 1.28 
8028 0.63 0.66 0.58 0.65 
8029 0.87 0.76 0.88 1.02 
8030 0.99 0.80 0.80 1.00 
8031 0.68 0.93 0.77 0.73 
8032 1.06 0.94 0.89 0.95 
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3.3.6 Plasma Triglyceride 
In the treatment arm the baseline median plasma triglyceride was 1.43 IQR 0.73 mmol/l. 
Following treatment with AGE it was1.45 IQR 0.77 mmol/l.  
In the placebo arm, the baseline mean plasma triglyceride was 1.59 IQR 1.19 mmol/l. 
Following treatment with placebo it was1.49 IQR 1.09 mmol/l. 
KS test showed the data to have a non parametric distribution. Friedman repeated measures 
ANOVA testing showed statistically significant difference (p=0.04) but this was between 
baselines, suggesting any perceived change post treatment would be difficult to interpret. 
The data for the subjects is shown in table 15. 
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Table 15: Changes in Plasma Triglyceride (mmol/l) 
Subject no Baseline Pre-Placebo Post Placebo Baseline Pre-AGE Post AGE 
8001 1.36 1.54 1.11 1.12 
8002 1.11 1.25 1.00 1.19 
8003 0.66 1.21 0.63 0.60 
8004 2.02 1.58 1.35 1.56 
8005 1.45 1.19 1.03 0.74 
8006 1.80 1.78 1.53 1.58 
8007 2.23 1.96 1.77 1.99 
8009 1.52 0.96 1.67 1.51 
8010 1.18 0.94 0.93 0.89 
8011 1.61 1.29 1.90 2.16 
8013 1.32 1.00 1.11 1.39 
8014 1.70 1.14 1.00 1.07 
8015 1.27 0.80 0.92 1.03 
8016 1.22 1.02 1.35 1.30 
8017 1.13 1.13 1.29 1.18 
8019 1.62 2.26 1.83 1.85 
8023 8.24 13.00 5.68 4.32 
8024 3.52 3.65 3.25 3.21 
8025 3.88 3.33 3.27 3.87 
8026 1.57 1.26 1.38 1.36 
8027 1.44 1.83 1.37 1.44 
8028 3.48 2.2 1.85 1.47 
8029 2.73 2.27 1.48 1.53 
8030 2.56 3.86 2.00 2.30 
8031 1.10 1.38 1.70 1.20 
8032 3.23 3.56 4.00 3.60 
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3.3.7 Fructosamine 
In the treatment arm, the baseline mean fructosamine was 272±32µmol/l. Following treatment 
with AGE it was 270±33µmol/l. 
In the placebo arm, the baseline mean fructosamine was 273±32µmol/l. Following treatment 
with placebo mean fructosamine was 270±33µmol/l. 
KS testing showed the data was distributed parametrically. Repeated measures ANOVA 
testing showed no statistically significant difference in either arm (p=0.88). 
The data for the subjects is shown in table 16. 
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Table16: Changes in Fructosamine (µmol/l) 
 
Subject no Baseline Pre-Placebo Post placebo Baseline Pre-AGE Post AGE 
8001 285 268 291 285 
8002 335 281  356 
8003 266 232 267 252 
8004 336 347 323 350 
8005 263 241 232 232 
8006 279 281 244 241 
8007 340 252 277 251 
8009 301 304 281 282 
8010 263 255 256 263 
8011 264 253 272 260 
8013 217 217 223 214 
8014 253 266 341 274 
8015 253 234 248 245 
8016 280 264 285 273 
8017 246 252 254 256 
8019 244 252 242 247 
8023 300 307 291 275 
8024 258 266 231 259 
8025 246 246 308 311 
8026 368 343 332 353 
8027 266 256 263 258 
8028 277 260 261 254 
8029 433 484 309  
8030 287 279 280 305 
8031 276 306 299 271 
8032 255 279 251 268 
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3.3.8 Insulin Resistance 
Insulin resistance was measured using the HOMA- IR method as described previously. In the 
treatment arm, the baseline insulin resistance was 1.89 ±1.1 units. Following treatment with 
AGE insulin resistance was 1.7±0.9 units. Repeated measures ANOVA testing showed this 
result to not be statistically significant (p = >0.05) 
In the placebo arm, the insulin resistance at baseline was 2.5±2.0 units whereas following 
treatment with placebo it was 2.0±1.1 units. Repeated measures ANOVA testing showed this 
result not to be statistically significant (p = >0.05) 
KS test showed the data to be parametrically distributed. Repeated measures ANOVA testing 
showed this result to have borderline statistical significance difference (P=0.05, n=26). Post 
hoc testing with Bonferroni supported this finding as non significant. 
The data for the subjects is shown in table 17. 
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Table17: Changes in Insulin Resistance 
Subject no Baseline Pre-Placebo Post Placebo Baseline Pre-AGE Post AGE 
8001 4.8 4.8 3.7 3.6 
8002 1.6 1.6 1.5 1.2 
8003 1.1 0.7 0.5 0.9 
8004 2.3 1.9 1.7 2.3 
8005 0.6 0.7 0.5 0.7 
8006 2.2 1.6 1.9 2.3 
8007 3.2 2.9 2.7 2.8 
8009 9.7 1.2 1.3 2.3 
8010 1.3 0.9 1.1 0.9 
8011 2.7 2.9 2.7 2.2 
8013 1.4 1.2 1.6 1.4 
8014 1.3 2.1 1.6 1.6 
8015 1.1 0.9 0.7 0.6 
8017 0.7 0.6 0.5 0.5 
8019  1 1 0.8 
8023 5.1 2.5 2.5 2.4 
8024 1.7 1.6 1.8 1.6 
8025 1.9 2.2 2.2 1.8 
8026 3.8 4.1 4.4 3 
8027 0.9 0.8 0.8 1 
8028 1.3 1.3 0.9 0.7 
8029 4 2.6 3.7 3.2 
8030 2.1 2.7 2.5 1.6 
8031 1.9 2 2.1 2 
8032 2.2 2.3 2.5 2 
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3.4 Markers of Endothelial Function  
3.4.1 Digital Plethysmography 
At baseline, the mean change in reflective index (RI) post GTN was 11±5.7%. Following 
treatment with AGE mean change in RI was 12±7.3%. In the placebo arm, at baseline the 
mean change in RI post GTN was 12.5±8.2% following treatment with placebo it was 
11±8.2%.  
KS test showed the data to be distributed in a parametric fashion. Repeated measures ANOVA 
testing showed no statistically significant difference in either arm (p=0.52). 
 The data for the subjects is shown in table 19. 
At baseline, the mean change in RI post salbutamol was 6.5 IQR 8.3% and following 
treatment with AGE it was 6.5 IQR 10.3%. The mean change in RI at baseline post salbutamol 
was 8.0 IQR 5.0%.  
KS testing showed the results to be distributed non-parametrically. A Freidman ANOVA test 
was used. This showed no statistical significant difference (p=0.95) in GTN or salbutamol 
responses following AGE or placebo. 
The data for the subjects is shown in table 18. 
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Table 18: Reflective Index change post Salbutamol (%mean) 
Subject no Baseline Pre-Placebo Post Placebo Baseline Pre-AGE Post AGE 
8001 8 4 1 1 
8002 5 11 16 21 
8003 4 0 1 13 
8004 9 16 7 5 
8005 14 16 11 15 
8006 4 2 0 6 
8007 9 3 6 3 
8009 20 12 11 2 
8010 8 2 6 12 
8011 8 10 6 18 
8013 0 1 1 1 
8014 4 0 13 5 
8015 12 13 27 29 
8016 9 11 4 2 
8017 6 14 2 7 
8019 4 10 5 13 
8023 18 9 11 10 
8024 9 7 10 3 
8025 0 9 12 7 
8026 9 4 1 7 
8027 7 11 7 6 
8028 9 0 3 2 
8029 19 17 4 10 
8030 0 13 24 15 
8031 6 1 11 2 
8032 6 6 7 4 
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Table 19: Reflective Index change post GTN (% mean) 
Subject no Baseline Pre-Placebo Post Placebo Baseline Pre-AGE Post AGE 
8001 30 15 9 19 
8002 13 12 16 16 
8003 6 6 13 9 
8004 10 3 8 20 
8005 10 12 2 4 
8006 14 3 15 16 
8007 23 25 10 16 
8009 11 12 16 16 
8010 1 7 10 8 
8011 4 2 0 3 
8013 13 10 10 2 
8014 12 10 9 12 
8015 10 7 8 21 
8016 28 23 21 9 
8017 7 0 9 7 
8019 2 2 2 3 
8023 31 27 16 28 
8024 9 2 3 6 
8025 9 17 12 15 
8026 14 19 15 20 
8027 0 9 5 8 
8028 13 12 12 7 
8029 15 19 19 19 
8030 20 26 22 21 
8031 14 3 9 12 
8032 6 3 13 0 
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3.4.2 Urinary Albumin /Creatinine Ratio (ACR) 
In the treatment arm, baseline median ACR was 0.55 IQR1.25. Following treatment with AGE 
the median ACR was 0.60 IQR1.03.  
The baseline median ACR in the placebo arm was 0.80 IQR 0.88. After treatment with 
placebo it was 0.65 IQR1.23.  
KS test showed the results to be distributed non- parametrically and therefore a Friedman 
Repeated measures ANOVA test was performed. This showed the result in neither arm to be 
statistically significant (p=0.43, n=26). 
The data for the subjects is shown in table 20. 
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Table 20: Changes in Urinary Albumin/Creatinine ratio 
Subject no Baseline Pre-Placebo Post Placebo Baseline Pre-AGE Post AGE 
8001 10.2 0.7 0.6 0.6 
8002 0.2 0.2 <2 <2 
8003 1.6 2.7 2.6 2.4 
8004 7.7 7.1 4.6  
8005 <2 0.3 <2 <2 
8006 0.2 0.2 <2 <2 
8007 0.3 0.2 0.6 0.2 
8009  <2 1 1.2 
8010  0.4 0.5 <2 
8011 0.4 <2 0.5 <2 
8013 0.1 <2 0.2 0.2 
8014 1 0.5 0.4 0.4 
8015 0.8 0.9 0.4 1.5 
8016 0.7 1.2 0.9 0.9 
8017 <2 <2 0.4 <2 
8019 0.8 0.4 0.5 0.6 
8023 0.8 0.6 0.5 0.6 
8024 0.3 <2 0.3 0.4 
8025 1.3 1.5 1.6 1.7 
8026 0.4 0.6 0.5 0.5 
8027 <2 0.3 0.4 0.5 
8028 0.5 0.3 0.3 0.4 
8029 5.3 4.3 4.3 1.9 
8030 <2 0.4 <2 0.3 
8031 1.5 2.3 1.8 1 
8032 0.8 0.5 0.4 0.5 
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3.5 Markers of oxidative stress 
3.5.1 Plasma Total Antioxidant Status (TAOS) 
In the treatment arm, plasma TAOS (expressed as ascorbate equivalent antioxidant 
concentrations -AEAC) at baseline was 63.1±3.2µM. Following treatment with AGE plasma 
TAOS was 64.0±4.4µM.  
In the placebo arm, plasma TAOS at baseline was 62.9 ±3.6µM. After treatment with placebo 
this was 63.6±5.6µM.  
KS test showed the data to be parametrically distributed. Repeated measures ANOVA testing 
showed the result in neither arm to be statistically significant (p=0.57, n=25). 
The data for the subjects is shown in table 21. 
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Table 21: Changes in TAOS (µM AEAC) 
Subject no Baseline Pre-Placebo Post Placebo Baseline Pre-AGE Post AGE 
8001 63.0 70.1 66.2 71.9 
8002 63.4 69.6 70.1 69.3 
8003 67.7 69.4 70.9 72.9 
8004 65.6 63.6 63.2 65.0 
8005 68.6 67.3 62.2 71.2 
8006 60.8 70.9 61.6 59.1 
8007 54.9 69.7 63.8 69.4 
8009 60.1 60.9 62.3 62.0 
8010 63.1 61.1 62.5 66.7 
8011 68.4 69.1 65.9 68.1 
8013 63.3 72.6 61.3 63.2 
8014 60.7 61.2 58.9 62.3 
8015 61.4 60.7 63.5 61.1 
8016 65.0 63.2 64.2 60.9 
8017 55.9 57.0 59.6 57.7 
8019 61.1 57.2 62.1 62.3 
8023 57.6 50.0 55.9 57.9 
8024 63.1 65.6 61.3 61.4 
8025 66.3 64.4 60.8 66.9 
8027 62.7 59.4 65.3 62.1 
8028 66.5 59.8 66.5 62.0 
8029 61.5 59.6 63.1 65.9 
8030 61.1 60.3 62.7 61.6 
8031 64.3 58.3 63.9 58.0 
8032 67.0 68.8 60.8 63.5 
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3.5.2 Glutathione ratio 
The median glutathione ratio (GSH/GSSG) at baseline in the treatment arm was 18.8 IQR 
21.8. After treatment with AGE it was 22.8 IQR 25.1. 
In the placebo arm, glutathione ratio at baseline was 17.0 IQR 15.1 and following treatment 
with placebo this was 20.6 IQR 22.5. 
KS test showed these results to be non-parametric in distribution. Freidman repeated measure 
ANOVA testing showed this result was not statistically significant (p=0.63).  
The data for the subjects is shown in table 22. 
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Table 22: Changes in Glutathione ratio (GSH/GSSG) 
Subject no Baseline Pre-Placebo Post Placebo Baseline Pre-AGE Post AGE 
8001 7.1 43.5 19.9 22.8 
8002 12.2 16.4 13.6 18.8 
8003 39.1 35.9 32.1 15.5 
8004 33.8 11.3 15.5 10.5 
8005 11.2 36.9 10.1 8.5 
8006 7.1 43.5 19.9 22.8 
8007 21.4 10.2 7.1 5.2 
8009 8.8 11.1 13.2 19.9 
8010 62.1 9.6 93.2 35 
8011 13.9 20.7 5.6 1.8 
8013 16 31.4 59.7 19.1 
8014 69.1 44.7 10.6 15 
8015 27.7 26.7 38.5 50.9 
8016 44.6 9.4 12 46.5 
8017 19.7 19.9 8.3 9.7 
8019 63.8 17.8 34.8 47.4 
8023 18.7 13.9 15.6 27.8 
8024 18.9 23.4 27.5 71.5 
8025 17.7 16.9 46.2 29.4 
8026 7.1 99.3 40.8 23 
8027 11 12.9 17.7 77.1 
8028 20.9 20.5 28.4 12.7 
8029 5.7 31.8 4.4 40.7 
8030 12.3 16.3 17.2 46.2 
8031 10.8 44.4 20.7 38.6 
8032 16.3 66.9 36 18.7 
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3.5.3 Whole blood glutathione 
The mean total whole blood glutathione at baseline in the treatment arm was 690.2 ±177.9µM. 
Following treatment with garlic it was 725.8 ±224.5 µM. 
In the placebo arm, at baseline the mean total whole blood glutathione was 698 ±193.7µM. 
following treatment with placebo it was 690.9 ±169.1µM. 
KS testing showed these results to have a parametric distribution. Repeated measure ANOVA 
showed there to be no statistically significant difference in either arm. (p=0.67). 
The data for the subjects is shown in table 23. 
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Table 23: Changes in total whole blood glutathione (µM) 
Subject no Baseline Pre-Placebo Post Placebo Baseline Pre-AGE Post AGE 
8001 338.2 393.6 530.2 406.5 
8002 539.3 791.5 434.2 771.2 
8003 852.7 697.0 595.8 630.7 
8004 575.9 487.9 475.5 472.1 
8005 560.3 672.9 562.5 672.9 
8006 416.6 486.3 507.9 537.8 
8007 724.4 557.5 472.7 489.3 
8009 387.5 414.6 574.2 592.5 
8010 744.8 707.6 951.7 657.6 
8011 593.8 731.7 471.8 343.8 
8013 770.9 914.3 811.3 978.6 
8014 876.0 768.8 780.9 704.7 
8015 756.4 845.8 919.9 1059.4 
8016 911.2 788.0 893.3 942.2 
8017 553.0 432.6 423.9 549.3 
8019 1143.8 762.6 833.6 939.6 
8023 712.9 874.1 808.8 738.2 
8024 898.3 729.6 779.4 1138.7 
8025 603.1 597.1 820.5 611.1 
8026 761.1 867.1 961.2 629.9 
8027 535.7 496.0 601.5 801.7 
8028 918.0 732.0 859.3 877.3 
8029 531.9 552.3 546.9 619.9 
8030 963.5 958.5 690.1 1209.9 
8031 715.6 746.4 883.0 910.0 
8032 763.6 949.6 755.5 587.7 
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3.5.4 Plasma Lipid Hydroperoxides (LHP) 
At baseline, the mean plasma LHP in the treatment arm was 144.7±55.4 µM. Following 
treatment with AGE this was 134.19±41.07 µM. 
In the placebo arm, mean plasma LHP at baseline was 158.3±97.0µM and following treatment 
with placebo it was 134.1±39.7 µM. 
KS testing showed the data to be distributed parametrically. Repeated measure ANOVA 
testing of this result failed to show statistical significance in either arm (p=0.41, n=24). 
The data for the subjects is shown in table 24. 
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Table 24: Changes in LHP (µM) 
Subject no Baseline Pre-Placebo Post Placebo Baseline Pre-AGE Post AGE 
8001 158.29 120.31 155.89 150.60 
8002 281.85 123.68 115.50 108.77 
8003 115.02 122.72 111.66 79.93 
8004 303.00 160.70 235.70 182.33 
8005 127.04 156.86 141.47 163.58 
8006 112.14 123.68 113.1 131.37 
8007 258.77 97.24 213.1 110.22 
8009 106.85 119.35 119.35 110.7 
8010 130.41 112.62 132.33 102.52 
8011 107.81 126.56 143.87 133.29 
8013 135.22 114.06 112.14 120.31 
8014 114.54 90.02 108.77 127.04 
8015 108.77 92.43 148.2 96.27 
8016 167.91 157.33 323.2 154.45 
8017 496.27 228.97 53.49 161.66 
8019 176.56 103.97 139.06 72.24 
8023 102.04 108.77 112.62 173.68 
8026 153.97 144.35 228.97 122.24 
8027 154.93 128.00 142.43 127.04 
8028 22.24 104.93 116.47 127.52 
8029 179.93 250.60 125.60 133.77 
8030 133.77 130.89 102.52 278.97 
8031 22.72 183.77 135.22 121.27 
8032 128.97 117.91 141.95 130.95 
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3.6 Markers of vascular inflammation 
3.6.1 Plasma high-sensitivity CRP 
The baseline median plasma hsCRP in the treatment arm was 2.1 IQR1.9 mg/l. Following 
treatment with AGE this was 1.83 IQR 2.11mg/l.  
The baseline median plasma hsCRP in the placebo arm was 1.8 IQR 2.3 mg/l. After treatment 
with placebo this was 2.0 IQR 1.8 mg/l.  
KS test showed the results to be of a non parametric distribution and therefore a Friedman 
(non parametric) Repeated measures ANOVA test was performed. This showed the result in 
neither arm to be statistically significant (p=0.90, n=26). 
The data for the subjects is shown in table 25. 
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Table 25: Changes in Plasma hsCRP 
Subject no Baseline Pre-Placebo Post Placebo Baseline Pre-AGE Post AGE 
8001 2.94 2.33 2.35 3.39 
8002 0.16 0.22 0.17 0.21 
8003 0.84 0.77 1.35 1.23 
8004 6.34 10.70 9.00 41.90 
8005 1.51 2.14 2.77 1.27 
8006 6.36 2.17 1.81 3.19 
8007 3.00 2.75 3.11 2.64 
8009 1.18 1.07 0.91 1.14 
8010 0.71 0.65 0.38 0.59 
8011 0.62 0.62 0.68 1.02 
8013 1.41 1.42 0.40 0.22 
8014 1.32 1.66 2.72 2.17 
8015 2.49 8.46 3.67 1.50 
8016 1.23 1.02 2.51 1.30 
8017 0.72 0.60 1.78 1.08 
8019 0.47 1.21 0.64 0.72 
8023 1.87 1.94 1.51 1.19 
8024 8.58 2.07 4.44 2.57 
8025 3.19 2.41 2.59 3.54 
8026 3.07 17.40 2.59 2.38 
8027 2.87 1.99 2.49 7.75 
8028 3.27 0.92 0.83 3.72 
8029 9.19 8.37 5.47 5.63 
8030 0.41 3.46 0.30 1.43 
8031 2.63 2.99 2.34 2.30 
8032 1.68 2.05 1.80 2.44 
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3.7 Summary of results 
Table 26: Summary of the effect of AGE and placebo on measured parameters 
Marker 
Mean Pre-
Placebo 
Mean post 
placebo 
Mean Pre-
AGE 
Mean post 
AGE 
P Value 
(ANOVA) 
Weight (kg) 98.7±18.5 98.8±18.4 98.2±18.2 98.7±18.2 0.24 
Systolic BP (mmHg) 130.3±15.9 131.6±17.5 130.3±14.0 130.8±14.6 0.94 
Diastolic BP(mmHg) 74.8±9.8 75.1±8.3 74.7±7.5 73.9±7.7 0.81 
Total Cholesterol 
(mmol/l) 
4.2±0.8 4.2±0.9 4.2±0.9 4.2±0.8 0.96 
Plasma HDL (mmol/l) 1.0±0.3 1.0±0.3 1.0±0.3 1.0±0.3 0.46 
Plasma Triglycerides 
(mmol/l) 
1.6 IQR 1.2 1.5 IQR 1.1 1.4 IQR 0.7 1.4 IQR 0.8 0.04* 
Fructosamine (µmol/l) 284±46 270±33 274±33 270±33 0.88 
RI post GTN (%) 12.5±8.2 11±8.2 11±5.7 12±7.3 0.52 
RI post Salbutamol 
(%) 
8.0 IQR 4.7 9.0 IQR 9.5 6.5 IQR 7.7 6.5 IQR 9.7 0.95 
Insulin Resistance 
(HOMA-IR) 
2.5±2.0 2.0±1.1 1.89 ±1.1 1.7±0.9 0.05* 
A/C Ratio 0.8 IQR 1.6 0.6 IQR 1.6 0.5 IQR 1.55 0.9 IQR 1.5 0.43 
HsCRP (mg/l) 1.8 IQR 2.1 2.0 IQR 1.6 2.0 IQR1.8 1.9 IQR 1.9 0.90 
TAOS (µM) 62.9 ±3.6 63.6±5.6 63.1±3.2 64.0±4.4 0.57 
GSH/GSSG Ratio 17 IQR 15.1 20.6 IQR22.15 
18.8 IQR 
21.2 
22.8 IQR25.1 0.63 
Total blood 
glutathione (µM) 
698.9±193.7 690.9±169.1 690.2±177.9 725.8±224.5 0.67 
Plasma LHP (µM) 158.3±97 134.2±29.7 144.7±55.4 134.19±41.1 0.41 
* = non-significant in post hoc testing 
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3.8 Subset Analysis 
Given previous studies had studied either only men [261] or found gender differences [265], 
we performed a gender subset analysis. This found no statistically or clinically significant 
differences between the baselines of men and women. The 2 values were compared using an 
unpaired t-test (See Table 27). Measured outcomes in both groups were analysed using 
repeated measures of ANOVA as previously mentioned and this delivered no significant 
results in either gender group (see Table 28). 
Table 27: Comparison of baselines in men and women 
Baseline Mean Value Men Mean Value Women 
Comparison of 
baselines (p=) 
Hba1c (%) 6.9±1.6 7.5±1.1 0.26 
BMI (kg/m
2
) 33.2±6.2 31.4±4.1 0.44 
Diastolic Blood 
Pressure (mmHg) 
75±10 75±9 0.97 
Systolic Blood 
Pressure (mmHg) 
129± 16 131± 16 0.86 
Total Cholesterol 
(mmol/) 
4.0± 0.6 4.7± 1.0 0.55 
HDL 1.0 ±0.3 1.1 ±0.2 0.68 
Triglycerides 1.9± 0.9 2.4± 1.1 0.99 
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Table 28: ANOVA analysis of men and women subsets 
Variable Measured ANOVA p value Men ANOVA p value Women 
LHP 0.65 0.51 
HsCRP 0.74 0.21 
TAOS 0.62 0.54 
GSH/GSSG ratio 0.71 0.75 
Total cholesterol 0.58 0.88 
HDL 0.34 0.96 
Triglycerides 0.02* 0.17 
RI Salbutamol 0.69 0.79 
Insulin Resistance 0.17 0.14 
*Triglycerides were only statistically significant as baselines were significantly different
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3.9 Associations 
For our secondary outcomes, we found baseline correlations between BMI (Body Mass Index) and 
Insulin Resistance (Spearman rank correlation P= 0.001, R =0.63), BMI and HsCRP (Spearman rank 
correlation P=0.004, R=0.54), BMI and TAOS (Spearman rank correlation P= 0.05, R=-0.39), BMI 
and GSH/GSSG ratio (Spearman rank correlation P=0.02, R= -0.44). All of these would be expected as 
it is well established that BMI is related to the above parameters. 
Insulin Resistance and GSH/GSSG ratio were also found to have an association (Spearman rank 
correlation P= 0.03, R=-0.43). However, when multiple regression analysis was performed to account 
for the effect of BMI, this association was no longer present. 
Endothelial function and CRP correlation showed a trend towards significance (P=0.08). All other 
correlations were found to be non-significant. 
Correlations were taken from baseline measures as no positive post treatment changes had been 
obtained.
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Table 29: Table of correlations 
Parameters Correlated R value (Spearman) P value 
BMI v Insulin Resistance 0.63 0.001* 
GSH/GSSG Ratio v Insulin 
Resistance 
-0.43 0.03* 
Insulin Resistance v HsCRP 0.27 0.19 
Insulin Resistance v RI (sal) 0.33 0.12 
Insulin Resistance v TAOS -0.25 0.24 
RI (Sal) v TAOS 0.07 0.72 
RI (Sal) v GSH/GSSG Ratio -0.14 0.48 
RI (Sal) v Tot Glutathione 0.27 0.17 
RI (Sal) v GSH/GSSG ratio -0.14 0.48 
RI (Sal) v HsCRP 0.34 0.08 
RI (Sal) v BMI 0.22 0.28 
TAOS v HsCRP 0.0015 0.99 
TAOS v BMI -0.39 0.05* 
GSH/GSSG Ratio v HsCRP -0.3 0.14 
GSH/GSSG Ratio v BMI -0.44 0.02* 
LHP v HsCRP 0.05 0.81 
LHP v RI (Sal) -0.02 0.9 
LHP v BMI -0.06 0.78 
BMI v HsCRP 0.54 0.004* 
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Figure 14. Correlation between BMI and Insulin Resistance 
---- 95% confidence interval   
 Linear Regression 
P= 0.001. n=26, r=0.63 
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Figure 15. Correlation between GSH/GSSG ratio and Insulin Resistance 
---- 95% confidence interval 
 Linear Regression  
 
3.11 Adverse Events 
Two subjects withdrew due to side effects from the medication, namely indigestion. Two 
subjects withdrew due to concurrent, unconnected illness. None of the data was used in the 
analysis. 
Ten subjects complained of mild indigestion or an unpleasant after taste. Many of the subjects 
also noticed a garlic odour. Three subjects complained of nausea but these mild side effects 
did not affect compliance as assessed by tablet count. 
 
P = 0.03, n=26, r = -0.43 
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Chapter 4: Discussion  
As a primary outcome, this study tested the hypothesis that AGE may improve endothelial 
function, oxidative stress, vascular inflammation and insulin resistance in high risk 
cardiovascular subjects with type 2 diabetes (defined as >30% CV risk over 10 years). The 
study also examined the effect of AGE treatment on other metabolic risk factors for 
cardiovascular disease. 
As a secondary outcome we aimed to study the associations between oxidative stress, vascular 
inflammation, endothelial function and insulin resistance to test the hypothesis that these 
biochemical processes are interlinked.  
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4.1 Previous clinical studies examining the effect of garlic upon metabolic parameters 
Table 30: Characteristics of previous clinical studies using garlic to examine metabolic parameters 
Author Design No of 
Subjects 
Duration 
of 
treatment 
Daily 
Dose 
On 
Statins 
On Anti - 
HTN 
medication 
Raised 
Chol 
(>5mmol/l) 
Raised 
BP 
(>140/90) 
Subjects 
with DM 
Present 
Study 
CO, PC 24 4 weeks 
1.2g 
AGE 
96% 46% 11.5% 31% 100% 
Williams 
et al [261] 
CO, PC 15 2 weeks 
2.4g 
AGE 
100% 100% 0% 0% 0% 
Budoff et 
al [242] 
Parallel, 
PC 
65 1 Year 
250mg 
AGE 
100% 97% 77% 46% 5% 
Duda et al 
[265] 
Long 70 30 days 
Garlic 
oil 
NS 100% NS 100% NS 
Durak et al 
[320] 
Parallel 11 6 months 
Garlic 
extract 
(1ml/kg) 
NS NS NS NS NS 
Durak et al 
[321] 
Long 23 4 months 
Garlic 
extract 
(1ml/kg) 
NS NS 100% NS NS 
Kosegolu 
et al [322] 
Long 17 30 days 
Garlic 
powder 
0% 0% 0% 0% 0% 
Weiss et al 
[260 ] 
CO, PC 11 6 weeks 
4ml 
AGE 
0% 0% 0% 0% 0% 
Steiner et 
al [ 332] 
CO, PC 56 
4-6 
months 
7.2g 
AGE 
NS NS 100% NS NS 
McCreadle 
et al [333] 
Parallel, 
PC 
30 8 weeks 
900mg 
AGE 
0% 0% 100% 0% 0% 
Zhang et 
al [335] 
Parallel, 
PC 
34 7yrs 800mg N/S NS 50% NS NS 
Gardner et 
al [236] 
Parallel, 
PC 
192 6 months 1.8g 0% 0% 100% 0% 0% 
Rahman et 
al [334] 
Parallel, 
PC 
23 13 weeks 5ml 0% 0% 0% 0% 0% 
van Doorn 
[275] 
Parallel, 
PC 
84 3 months 2.1g 0% 0% 0% 0% 0% 
Abbreviations: CO = Crossover, PC = Placebo controlled, HTN = hypertensive, NS = not stated, Long = longitudinal
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The current study found no significant effect of 4 weeks treatment with 1200mg daily of Aged 
Garlic Extract on the metabolic parameters studied in our cohort of subjects. There were some 
associations at baseline between BMI and insulin resistance, BMI and HsCRP, BMI and 
TAOS, BMI and GSH/GSSG ratio. There was also an association between insulin resistance 
and GSH/GSSG ratio but when BMI was factored for, this association was no longer present. 
To date few clinical studies have examined the effects of garlic preparations on oxidative 
stress, endothelial function or vascular inflammation. Most of the current evidence consists of 
in vitro and animal model studies. Previous clinical studies are summarised in table 27 and 
discussed below. 
4.1.1 AGE and oxidative stress 
Previously, Budoff et al [242] investigated the effect of AGE treatment upon markers of 
oxidative damage in subjects at moderate cardiovascular risk. This randomised, parallel, 
placebo controlled study of 65 individuals employed treatment with ‗AGE plus‘ (AGE + 
Vitamin B6+Vitamin B12+folate+L-arginine). The markers of oxidation studied were 
oxidised phospholipids/apoprotein B ratio and malondialdehyde epitopes on apolipoprotein B-
100. These are markers of oxidised LDL and represent oxidative damage and have a potential 
role in the pathophysiology of atherosclerosis. This study showed a statistically significant 
improvement in these markers after treatment with AGE plus. The strengths of this study lie in 
its long duration and relatively large numbers. Furthermore, it employed oxidative stress 
markers that have correlations to angiographically-determined coronary artery disease and 
cardiovascular disease prognosis [316]. The weaknesses included that the study used a mixture 
of antioxidant compounds and it is not clear which was the active ingredient. All of the 
participants were treated with statins and the majority were treated with antihypertensive 
 131 
 
medication and therefore were not dissimilar to our cohort. Only 4% of the subjects had 
diabetes. 
However, the findings of the Budoff study have not been consistently replicated. Williams et 
al [261] investigated the anti-oxidant effect of AGE on men with established coronary artery 
disease in a crossover study of 15 subjects. In this study 2.4g/day of AGE was used for a 
period of 2 weeks. None of the participants had diabetes. Plasma markers of oxidative stress 
were used (FRAP, Ox-LDL and peroxides). Ox-LDL and peroxides are markers of oxidative 
stress induced cell damage, whereas FRAP (Ferric reducing ability of plasma) is a marker of 
total antioxidant status. FRAP assays may not detect the actions of all antioxidants in the 
plasma, particularly thiols, and therefore may not have been the most suitable assay to study 
the effect of AGE [317]. 2 weeks treatment with AGE failed to have a significant impact upon 
these oxidative stress markers. These subjects did have known endothelial dysfunction at 
baseline but it is not known whether their oxidative stress markers were abnormal at baseline. 
Furthermore, this study did not use a control group. All the subjects in this study were treated 
with aspirin and statins which could confound any effect of AGE given these agents also have 
antioxidant effects. 
Duda et al [265] studied the effect upon oxidative stress markers of a garlic oil extract in 70 
patients with hypertension. This was an uncontrolled, longitudinal study which demonstrated a 
statistically significant reduction in markers of lipid oxidation after 30 days of treatment. The 
marker of oxidative stress used was lipid peroxidation products reacting with thiobarbituric 
acid (TBARS.) This study also looked at antioxidant potential using hemolysate total 
glutathione levels (GSH) and glutathione peroxidase activity. The study found a significant 
increase in GSH levels in women only and no significant change in glutathione peroxidase 
activity. The study also examined plasma levels of the antioxidant vitamins A, C and E, but 
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only levels of vitamin E improved significantly. 80% of the subjects in this study were treated 
with a combination of antihypertensives (mainly ACEI). The authors found no significant 
decrease in blood pressure in this study but did find a significant 9.2% reduction in plasma 
total cholesterol concentration. The authors concluded that the small changes in markers of 
oxidative stress seen have uncertain clinical implications. The marker of oxidative damage 
used (TBARS) employs thiobarbituric acid to detect malonaldehyde (MDA), a product of lipid 
peroxidation.  This method has been criticised as lacking specificity [318]. Blood MDA is 
metabolised rapidly and may only represent 1% of total lipid peroxides [319]. Total GSH  and 
glutathione peroxidise activity are both markers of single antioxidants  and given the complex 
interaction between antioxidants may be too simplistic a measure of in vivo oxidant status 
[317].This study also examined the effect of garlic oil which has different antioxidant 
components than those found in AGE. It is unknown how many of the subjects had diabetes or 
were treated with a statin. 
Durak et al [320] performed a clinical study in 11 subjects with atherosclerosis examining the 
effect of a garlic extract upon markers of oxidative stress. This study employed a control 
group of healthy subjects but no placebo was involved. The subjects were treated with a 
number of cardiac medications throughout the study but the baseline characteristics of the 2 
groups were not described. The garlic extract used was created using a short term aqueous 
extraction process in the author‘s laboratory and, whereas the antioxidant capacity was 
standardised, the active ingredients were not established. This was given in large doses 
(1ml/kg) for a period of six months.  The markers of oxidative stress used were erythrocyte 
and plasma MDA and a measurement of antioxidant enzymes though this was poorly 
described. The authors found that after 6 months of garlic extract treatment there was a 
reduction in plasma and erythrocyte MDA but there was no effect upon antioxidant enzyme 
activity. However, the published details of this study were insufficient to allow critical review. 
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A further study by Durak et al [321] investigated the effect of the same garlic extract on 
markers of oxidative stress in subjects with high plasma cholesterol concentration 
(>5.98mmol/l). This was an uncontrolled, longitudinal cohort study.  The 23 subjects were 
further divided into hypertensive (>140/90mmHg) and a normotensive group. The extract was 
administered at 1ml/kg for 4 months. This study showed statistically significant changes in all 
the markers of oxidative stress investigated (Plasma MDA, oxidation resistance, antioxidant 
potential, nonenzymatic superoxide radical scavenger (NSSA) activity). The clinical relevance 
of these results is uncertain. It is unclear whether the subjects had diabetes or were treated 
with other medications. 
 
Kosegolu et al [322] studied the effect of garlic powder upon plasma total antioxidant capacity 
(TAC) in 17 young (mean age 35), healthy volunteers. This was an uncontrolled, longitudinal 
cohort study using dried garlic powder for a period of 30 days. This study showed there to be a 
statistically significant increase in plasma TAC after treatment with garlic. Whereas this is not 
a widely used assay, it did measure total antioxidant capacity of the plasma and is based on a 
widely used measurement Total Equivalent Antioxidant Capacity [317]. However, this study 
used a very different subject group, a different garlic preparation and did not have a control 
arm or a placebo. 
 
This study used a small dose of AGE for a period of 4 weeks. Our results are consistent with 
the study of Williams et al but the Budoff study suggests a larger dose for a much longer 
period of administration (>12 months) may be necessary to have an effect upon oxidative 
stress markers in a cohort treated with statins. The Dillon study [243] suggests that other 
markers of oxidative stress may change more rapidly but it may be that measurement of F2-
isoprostane 8-iso-prostaglandin is more sensitive than other markers of oxidative stress.  
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4.1.2 AGE and endothelial function 
Weiss et al [260] investigated the effects of AGE on flow mediated dilatation in the brachial 
artery after induced acute homocysteinaemia. Acute homocysteinaemia gives experimentally 
induced endothelial dysfunction by reducing bioavailable nitric oxide at the endothelium. This 
cross-over study of 11 healthy individuals found subjects treated with AGE had a 66% 
increase in flow mediated dilatation in the brachial artery, as measured by Doppler ultrasound, 
in comparison with the placebo-treated subjects. However, there was also a significant 
decrease in plasma homocysteine concentrations after treatment with AGE which has a direct 
endothelial effect. Furthermore, this study recruited a very different cohort to ours (relatively 
young, healthy individuals with no cardiac risk factors or diabetes) and small numbers. 
Williams et al [261] investigated the effect of AGE upon endothelial function in men with 
established coronary artery disease in a crossover study of 15 subjects. In this study 2.4g/day 
of AGE was used for a period of 2 weeks. This study employed ultrasound and Doppler 
measured brachial artery flow mediated dilatation (FMD) as a measure of endothelial function 
and found a significant improvement following treatment with AGE over placebo. The 
limitations of this study include its small numbers and the relatively short duration of 
treatment. This study investigated non diabetic subjects and all of the subjects were treated 
with statins and aspirin.  
Budoff et al [242] investigated the effect of AGE treatment on microvascular endothelial 
function in subjects at moderate cardiovascular risk. This randomised, placebo controlled 
study of 65 individuals used 1 year‘s treatment with AGE plus (AGE + Vitamin B6+Vitamin 
B12+folate+L-arginine) and measured endothelial function using digital thermal monitoring. 
This is a mechanism which measures temperature rebound in the hands after a period of 
occlusive hyperaemia (blood pressure cuff on forearm). These investigators found AGE 
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significantly increased temperature rebound. This study also discovered significantly reduced 
coronary artery calcium progression (a marker of atherosclerotic plaque progression) after 
treatment with AGE. Subjects were all treated with statins and 97% were treated with 
unspecified antihypertensive agents. Only 5% had diabetes. However, as the agent used was a 
mix of antioxidants, it is difficult to extrapolate these results to AGE used in isolation. The 
temperature rebound method of measurement of endothelial function lacks reproducibility and 
the skin‘s role as important thermoregulatory organ may mean that vasoreactivity in this organ 
is not synonymous with other capillary beds [323]. Moreover, the occlusive hyperaemia model 
for testing endothelial function may not be a purely nitric oxide induced phenomenon and 
there is a complex of mechanisms involved [324]. As a result, occlusive hyperaemia may be a 
poor surrogate marker for endothelial function. 
In the present study, digital photoplethysmography was used as a marker of endothelial 
function and found no significant change after garlic or placebo treatment. This may be due to 
the dose and length of AGE treatment used, which is lower and shorter respectively than some 
of the studies mentioned above. It may also be that digital plethysmography is a less sensitive 
tool than FMD for measuring changes in vasomotor activity [325] and as a result we were 
unable to detect any change. 
4.1.3 AGE and inflammation 
There have been a small number of previous clinical studies examining the effect of AGE on 
circulating inflammatory markers. Williams et al [261] studied the inflammatory markers 
CRP, interleukin 6 and VCAM-1 and found that 2 week treatment with AGE had no 
significant effect. 
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CRP is a robust, stable biomarker, with a well standardised assay and an association with 
clinical outcomes [263, 264, 326, 327, 328]. The lack of effect in the Williams study may have 
been due to a relative short exposure to AGE. By contrast, Interleukin -6 has only a very short 
half life and therefore its measurement in plasma is technically difficult and may explain the 
negative result [326]. V-CAM 1 is thought to exhibit significant diurnal variation [329] and 
assays lack standardisation [268]. These may account for the failure to detect any change in 
this study.   
 Budoff et al [242] used AGE plus, a combination of agents, for a much longer period (12 
months) and on more subjects (n=65) than the Williams group. Despite this, AGE was found 
to significantly reduce markers of oxidative stress but not a circulating inflammatory marker 
(hsCRP).  
There is evidence that CRP exhibits diurnal variation (up to 34%) and only a small (non 
significant) seasonal variation [330]. The seasonal variation may have been playing a part in 
the Budoff study but is less likely to be important in this study and the Williams study given 
the short treatment times. In this study and the Williams study all subjects were sampled in the 
early morning. No mention of sampling times was made in the Budoff study and this could 
partly explain the lack of effect. 
In respect to the ability of AGE to reduce markers of inflammation, this study supports these 
previous findings in that AGE had no significant effect upon circulating CRP, probably the 
most reproducible marker of inflammation.  Both the present study and the Williams study 
could be criticised for a relatively short duration of treatment, though this was addressed in the 
Budoff study. However, it must be recognised that all the studies involving CRP and AGE 
have used small numbers (n =15-65) and therefore may lack the power to allow reliable 
interpretation. 
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4.1.4 AGE and insulin resistance 
Currently, the effect of AGE or other garlic preparations upon insulin resistance has not been 
studied in clinical studies. The present study suggested that there was no effect on insulin 
resistance in our subjects after 4 weeks of treatment with AGE.  
If oxidative stress and inflammation are integrally linked to insulin resistance as discussed in 
the introduction chapter then the antioxidant capacity of AGE may have had an effect upon 
endothelial function in the tissues involved in glucose disposal and thus have a positive effect 
upon insulin resistance. 
4.2 AGE and traditional risk factors for cardiovascular disease 
4.2.1 Blood pressure 
There have been few studies investigating the hypotensive effects of AGE. AGE has been 
used to reduce blood pressure in hypertensive rodent models but not in diabetic models [331, 
235]. In clinical studies, Steiner et al [332] found that 26 weeks treatment with 7.2g daily of 
AGE reduced blood pressure in normotensive individuals by 5.5%. Of note, this was a placebo 
controlled, crossover study of 41 individuals which had crossover arms of different durations 
(4 months and 6 months) and had a poor compliance rate in the AGE group (<80%). This 
study was also designed as a study to investigate cholesterol reduction rather than 
hypertension. It used very large doses and had a high dropout rate (21%) which left it with 
relatively small numbers. 
 Further studies using AGE on BP have all shown no effect [261, 333]. McCreadle et al [333] 
administered 900mg AGE for 8 weeks but had a very different cohort; studying the effects in 
hypercholesterolaemic children. It is difficult to extrapolate these results to adults. 
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 4.2.2 Lipid Metabolism 
Whilst there is in-vitro evidence to suggest AGE may have cholesterol lowering properties, 
clinical studies have largely shown no significant statistical or clinical effect (see introduction 
chapter). The present study showed no significant change in total cholesterol, HDL or 
triglycerides over the 4 week study period. 
In previous studies, Steiner et al [332] demonstrated a modest 7% reduction in total 
cholesterol concentrations (0.4-0.52mmol/l) after 7.2g AGE supplementation for 6 months. 
Unlike the present study, the subjects in this study were not on statins, did not have diabetes 
and were hypercholesterolaemic.  
 A more recent study by Budoff [242] used an antioxidant combination including AGE and 
was of long duration (1 year). This study found a significant reduction (8.8%) in total 
cholesterol and this was in addition to statin therapy.  As mentioned previously, this study 
employed a combination of antioxidants therefore it is difficult to attribute this effect to AGE 
alone. 
Further studies have failed to replicate this effect on lipid metabolism and have shown no 
effect of AGE treatment over placebo [236, 261, 334, 335].  
Zhang et al [335] performed a small study (n=12 in each arm) for a long period (7 yrs) but 
used a very different cohort to the present study (rural Chinese subjects with precancerous 
gastric lesions) and investigated a mix of garlic supplements and therefore it is difficult to 
interpret these results. 
Gardner et al [236] studied several different preparations of garlic in 192 individuals without 
hypercholesterolaemia for 6 months. There were 48 subjects in the AGE group but none had 
diabetes or hypertension. 
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The Rahman Study [334] was a cohort study and not placebo controlled. Moreover, it was 
carried out in 23 young, healthy normocholesterolaemic individuals using 5ml of AGE over 13 
weeks. This makes extrapolation of these results to those patients/subjects with disease states 
difficult. 
Williams et al [261] also failed to show any effect of AGE on normocholesterolaemic 
individuals. A similar study by van Doorn et al [273] compared garlic powder, atorvastatin (an 
established HMG-CoA reductase inhibitor) and placebo, and found that garlic and placebo had 
no significant effect on plasma lipids after 3 months whereas atorvastatin reduced total plasma 
cholesterol by 37%. This would suggest any modest hypocholesterolaemic effect of AGE 
would be dwarfed by co-administration of a statin. It may be that the relatively small numbers 
used in this study did not allow detection of the small reduction seen in cholesterol levels by 
AGE in addition to statins. Furthermore, both Steiner and Budoff  used longer treatment 
durations (6 months and 1 year respectively) suggesting longer treatment with garlic may be 
necessary to reduce cholesterol, particularly when used in addition to statins therapy. 
 
4.3 Associations 
As no significant findings were obtained following treatment with AGE, associations were 
studied at baseline. No correlation was found between markers of oxidative stress, 
inflammation, endothelial function and insulin resistance. There was no correlation between 
HbA1c and oxidative stress markers, inflammatory markers or endothelial function. 
Despite significant pathophysiological evidence suggesting a link between oxidative stress, 
inflammation, endothelial function and insulin resistance, clinical studies investigating 
correlations between these processes have led to mixed findings.  
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Song et al [377] studied the relationship between oxidative stress markers, DNA damage and 
insulin resistance in 283 patients with normal glucose tolerance, impaired glucose tolerance 
and type 2 diabetes. The group found a positive correlation between insulin resistance and 
markers of oxidative damage and an inverse relationship between insulin resistance and anti-
oxidant defence.  
Rizzo et al [378] studied 13 obese men with impaired fasting glucose, but not diabetes, before 
and after 4 weeks administration of combined vitamin E and C. This study found an 
independent inverse correlation between plasma levels of Vitamin E and oxidative stress 
markers (plasma [8-] isoprostane levels and TNF-alpha levels). However, no correlation was 
found with other inflammatory markers or with glucose disposal. 
De Matia et al [379] studied the effects of GSH infusion on glucose handling in 10 healthy 
subjects and 10 subjects with type 2 diabetes. This study found an increase in glucose handling 
and intraerythrocyte GSH/GSSG levels in both groups and only found a correlation when both 
groups‘ data were pooled. 
McSorley et al [380] studied 28 healthy, young subjects who were the offspring of individuals 
with type 2 diabetes. This study found a link between insulin resistance and vasoactive 
endothelial function. They also studied the effect of vitamin E on these parameters but found 
no effect. 
Kar et al [293] found treatment with the antioxidant Grape Seed Extract (GSE) improved 
markers of glycaemic control, inflammation and oxidative stress. This was an in vivo study 
examining a very similar cohort to the present study using a similar methodology. Kar et al 
however found failed to find any correlations between markers of oxidative stress, insulin 
resistance, inflammation and endothelial function. 
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Many of the above studies were small studies and associations may not have been detectable 
with these numbers and the markers used. In the present study, the lack of treatment effect 
made the study of associations limited. The only significant associations were linked to BMI 
at baseline.  This may suggest adipose tissue could be a potential source of the inflammation 
and oxidative stress in our patient group. Adipose tissue has been well established as a 
potential source of a variety of cytokines and cellular components of the inflammatory process 
[397-401]. However, as yet this remains an association rather than a causative effect. 
Associations were calculated using the spearman rank correlation and in cross-over studies it 
can be argued that this method does not take account of the periodicity (i.e the order in which 
the treatments were administered). Nor does this method take account of any carry-over effect, 
ie an assessment of the adequacy of the wash out period. A statistically more robust method 
may have been to use linear mixed modelling. Although the numbers used in the current study 
would not have allowed linear mixed modelling to detect any change due to periodicity or 
carry over [396].
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4.4 Limitations of present study 
4.4.1 Cohort 
In the present study, the baseline oxidative stress markers and vascular inflammation were 
assumed to have been raised in the diabetic population examined [381,382]. However, a 
control group without diabetes was not employed, nor have previous studies using these 
markers established a normal level in healthy individuals.   
Our cohort of diabetes patient had reasonably well controlled metabolic parameters which met 
many of the NICE treatment guidelines [315]. Many of our subjects continued to take diabetic 
and vascular medications (statins [273], ACEI [336], Aspirin [318] and metformin [265]) 
throughout the study, all of which have been shown to have anti-inflammatory effects.  This 
suggests the subjects may have had relatively normal levels of oxidative stress and vascular 
inflammation at baseline and therefore any effect of AGE would have been difficult to detect. 
Moreover, any effect of the AGE treatment may have been attenuated by concurrent 
medication use. 
The subjects in the present study were also treated for only 4 weeks with AGE, which is 
similar to previous studies. It could be that this is insufficient time for oxidative stress markers 
to change. However, a longer study [242] showed significant changes in markers of lipid 
oxidation but no changes in HsCRP. 
Although, the numbers of subjects studied was relatively small, this study was still the largest 
of its kind investigating oxidative stress markers in subjects with type 2 diabetes. However, 
our power calculations suggest these small numbers may mean that the study was 
insufficiently powered to detect any changes using the markers we used in a group with near 
optimal metabolic control therefore this study could only be used as a pilot study. 
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The garlic extract used was not palatable for some subjects and the side effects of indigestion 
and ―repeating‖ was relatively common. We performed a tablet count to assess compliance, 
however this may not be reliable and it could be that compliance was lower than we assumed. 
The trial was designed to be double blind and indeed the placebo and the garlic tablet looked 
and smelled the same due to the addition of a drop of liquid AGE to the placebo container. 
Anecdotally, many of the subjects mentioned they could tell the capsules apart as the garlic 
capsules left a taste and smell of garlic after administration.  The subjects were not asked to 
guess which tablets they were taking so comparison of these results to the unblinded results 
does not allow any indication of how successful the blinding had been. 
We did not assess dietary garlic intake amongst our subjects. This is consistent with previous 
studies and in line with the manufacturer‘s advice. It is thought that the concentration effect of 
the extraction process 1200mg/day AGE would give the same antioxidant content as 7 cloves 
of raw garlic (12g dry weight), which would overwhelm any effect of dietary garlic 
(manufacturers correspondence and [335]. However, our subjects verbally confirmed that they 
were not taking garlic supplements in their diets. 
4.4.2 Methodology 
This study was a double blind, randomised cross over trial with four weeks of 
treatment/placebo and then 2 weeks washout followed by 4 weeks of treatment/placebo. This 
method allowed the subjects to act as their own controls and reduces inter-individual 
discrepancies. It was assumed that the baseline endothelial function, vascular inflammation 
and oxidative stress were all abnormal in our diabetic subjects in keeping with previous 
studies [243, 304, 327]. However, in this study the baselines did return to previous baseline 
after the washout period in all subjects. 
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This study used a Bonferroni method for ad hoc analysis of the variables studied. Bonferroni is 
a widespread method used in many scientific papers to add a further level of scrutiny to the 
potential of a chance finding (type 1 error) in those investigations of multiple variables [445]. 
However, Bonferroni method has been criticised in clinical trials as fundamentally examining 
the wrong question. Bonferroni will only tell us whether there is a statistical difference in the 
variables but will not tell us which variables differ [446]. The results also depend on how 
many variables have been examined in each study, which is often not clinically relevant 
[445,447]. The bonferroni method also is likely to increase type 2 errors [446] (the likelihood 
of falsely accepting the null hypothesis) which could mean clinically relevant changes are 
rejected. Use of the bonferroni method for statistical analysis in this study could have been too 
conservative to detect a meaningful clinical outcome.  
4.3.3 Endothelial function 
The present study employed digital photoplethysmography measurement of the pulse wave 
contour as a marker of the vasomotor aspect of endothelial function. Digital 
photoplethysmography studies the resistance vessels of the microcirculation and thus the 
blood flow. It uses easily available pharmacological stimulants to distinguish between 
endothelial effects and smooth muscle effects on vascular tone. This method has the 
advantages of non-invasive, pain-free measurement of the digital pulse wave contour allowing 
it to be used in larger numbers of subjects. It is also a relatively inexpensive method and is 
operator independent [337]. The method has also been studied in diabetic subjects [304] and 
has been shown to correlate with flow mediated dilatation studies [338]. However, some have 
criticised the techniques‘ reproducibility [339] and it lacks association with clinical end points 
[323].  Flow mediated dilatation studies probably remain the best method of non-invasively 
assessing vasomotor endothelial function, both in reproducibility [339] and in correlation with 
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clinical end points [340].  However, this method is expensive, is dependent upon the skill of 
the operator and requires lengthy training in its use [323, 341]. 
Microalbuminuria describes small amounts of protein loss in the urine. It is defined as 30-
300mg of albumin in the urine over 24 hours. A more practical, spot test of urinary 
Albumin/Creatine ratio of <2 has also been validated for clinical use [342]. The relationship 
between endothelial function and microalbuminuria is a complex one and not fully understood 
[308] but it is thought to be due to protein leakage through dysfunctional renal glomerular 
capillaries and as such is viewed as a reflection of systemic endothelial dysfunction. 
 Both endothelial function and microalbuminuria have been proven to predict cardiovascular 
outcome [343-345]. Many studies have shown an association between vasoactive endothelial 
dysfunction in those with diabetes and microalbuminuria [307-312]. Microalbuminuria has 
been shown to be correlated with endothelial dysfunction and plasma hsCRP levels in type 2 
diabetes [307] and with insulin resistance [312]. Reduction of microalbuminuria with ACEI 
has also been shown to improve cardiovascular outcomes independently of effects on blood 
pressure [346], although whether this is through amelioration of endothelial dysfunction is 
unclear [347, 348]. 
 Urinary Albumin Creatinine Ratio was utilised in the present study as a measurement of 
microalbuminuria. At baseline, only 4 of our subjects exhibited microalbuminuria and 
therefore it was unsurprising no difference was detected following treatment with AGE. 
Furthermore, baseline changes in reflective index following administration of salbutamol in 
our patients were in the range 6.5-8%. This is much closer to the control group (5.9%) cited by 
Cheowiencyzk‘s et al [304] rather than the diabetes group (11.5%), suggesting our cohort did 
not have significantly deranged endothelial function pre-treatment. 
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4.3.4 Oxidative stress markers 
Measurement of plasma markers of oxidative stress failed to detect a significant difference 
between AGE and placebo treatment. Direct measurement of oxidative stress in plasma is very 
difficult given the extreme reactivity of the free radicals and therefore markers of oxidant 
status or oxidative damage are used.  Measurement of specific antioxidant levels can be 
misleading as there is a complex interaction between all antioxidants in the system [317]. For 
example, when vitamin E is oxidised it is regenerated by both vitamin C and GSH. Therefore, 
a marker of total antioxidant status would give a more biologically significant result [349]. We 
used TAOS and whole blood GSH/GSSG ratio, both measures of total antioxidant status. We 
also used plasma lipid hydroperoxides (LHPs) as a marker of oxidant damage to give a marker 
of overall oxidative stress. 
Plasma TAOS, whole blood GSH/GSSG ratio and LHP‘s have all been used as markers of 
oxidative stress in previous studies. [350-353]. Plasma TAOS has been associated with 
cardiovascular outcomes [354]. However, metformin [355], ACEI [356], statins [273] and 
aspirin [357] have all been suggested to reduce oxidant stress which may confound 
interpretation. 
 
 
4.3.5 Circulating markers of inflammation 
There was no improvement in hsCRP following treatment with AGE or placebo. Both diabetes 
and obesity have been proven to be states of low grade inflammation [320-322], though the 
source of this inflammatory load remains uncertain [346, 347]. HsCRP has been used in 
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numerous previous studies as a marker of inflammation. It has been proven to be robust [358], 
stable [359] and predictive of future vascular events [360, 361, 362]. 
The baseline plasma hsCRP in the present study was lower than similar studies [383, 384] 
(Jupiter study baseline 4.2mg/l our baseline 2.07mg/l and Korean study 3.0mg/l). The Jupiter 
study did also not include any subjects with diabetes and only 16% were treated with aspirin 
[383]. Furthermore, the group treated with Rosuvastatin in the Jupiter trial had a post-
treatment plasma HsCRP of 2.2 mg/l; still higher than the pre-treatment baseline in the present 
study. 
Metformin has been linked to a reduction in hsCRP [385]. However, a more recent study in 
patients with similar baseline characteristics and treatments as our subjects, found no effect of 
metformin on circulating markers of inflammation [386].  Statins [247] and aspirin [357] have 
been associated with reductions in circulating hsCRP levels and it could be that the low 
baseline measurements of hsCRP were due to the actions of these medications. Furthermore, 
in a head to head study of a statin and garlic powder in an overweight population of smokers, 
(high inflammatory load), the statin significantly reduced hsCRP whereas garlic had no effect 
[247]. It is also possible that the cohort in the present study simply were a ―low inflammation‖ 
group due to current therapy, reflecting their well controlled metabolic baseline state despite 
the presence of  both diabetes and obesity (mean BMI =32.2kg/m
2
). 
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4.3.6 Measurement of insulin resistance 
Insulin resistance is the cornerstone pathophysiology in type 2 diabetes and describes a state 
where there is a reduced biological effect for a given concentration of insulin. Insulin 
resistance is a complex interaction of many dynamic biochemical and physiological processes 
and therefore direct measurement in vivo is difficult. The gold standard test for insulin 
resistance is widely accepted as the euglycaemic glucose clamp which measures direct whole 
body glucose disposal at a given level of insulinaemia under steady state conditions [387, 
388]. However, the use of clamps is costly and time consuming and there are some doubts 
about the intersubject variability (up to 46% in type 2 diabetes) [389]. This makes the use of 
this technique difficult for larger studies. 
To overcome the practical difficulties of direct measurement of insulin resistance, several 
mathematical models have been derived to give surrogate indices. The Homeostasis 
Assessment Model (HOMA) is a mathematical model which allows values for insulin 
sensitivity/resistance to be obtained if simultaneous fasting plasma glucose and fasting 
insulin/C-peptide are known. Since insulin secretion is pulsatile, this method uses the mean of 
three results at 5-min intervals (0, 5, and 10-min samples) [285]. 
HOMA modelling has been shown to be an appropriate method for assessing changes in 
insulin resistance with time in individuals, is robust and correlates well with euglycaemic 
clamp studies [387, 390]. This method is also inexpensive and simple to use [388], making it 
feasible in many circumstances. 
HOMA is a surrogate measure of insulin resistance and therefore has limitations. It is also a 
measure of basal insulin resistance which is largely determined by hepatic insulin resistance. 
Our hypothesis may suggest that skeletal muscle glucose handling is more likely to be affected 
by endothelial dysfunction; therefore measuring basal insulin resistance may mean potential 
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changes are not being detected. Measuring stimulated insulin resistance may have given a 
better indication of skeletal muscle capillary bed recruitment.  
 
4.4 AGE as a therapeutic agent 
This study employed Aged Garlic Extract as a preparation of garlic because its contents are 
standardised [233]; it has proven safety data and has been used extensively in similar clinical 
studies [238, 239,242, 243, 260, 261, 332, 369]. It also has extensive in-vitro data in 
comparison with other preparations and it has been suggested that AGE may have more potent 
anti-oxidant potential than other garlic preparations [247- manufacturers report].  
However, much of the research examining AGE has been conducted in the manufacturer‘s 
laboratories and by employees of the company and the results published in journal 
supplements (non peer reviewed) edited by company employees [391] and this has the 
potential to introduce bias. 
The bioavailability of AGE thiosulphates has been questioned [392] and the results of clinical 
studies upon markers of inflammation and oxidative stress have been mixed [242, 243, 261]. 
Therefore, the present results are not inconsistent with previous findings. The present study 
was also of a relatively limited duration and there have been studies using larger doses and 
longer durations [242] but with similar results.  
 
4.5 Conclusion and future direction 
Treatment of our subjects with AGE showed no significant effect upon markers of oxidative 
stress, endothelial function, inflammatory markers or insulin resistance in type 2 diabetes in 
comparison with placebo. The potential reasons for these findings have been discussed. In 
particular, a baseline of near optimal metabolic control and concurrent administration of 
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vasoactive medications in our cohort could have been responsible for our inability to detect a 
response with AGE.  
Future consideration should give rise to the use of a different subject cohort with the addition 
of inclusion criteria such as those with poor metabolic control at baseline. Exclusion criteria 
could include those on vasoactive medications, which would most likely represent those 
patients quite early in their diabetes diagnosis and who therefore had not been previously 
treated with other cardiovascular modifying medication. 
Consideration should also be given to increasing the treatment period of AGE given that the 
evidence would suggest the use of a longer period of exposure to AGE may be necessary, 
particularly in those taking other cardiovascular modifying medications. 
Furthermore, consideration should also be given to a longitudinal study looking at the effect of 
AGE supplementation upon clinical outcomes in high risk cardiovascular subjects. This would 
determine whether the changes in surrogate cardiovascular risk markers seen in relatively 
short studies elsewhere reflect changes in clinical outcome. 
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